WO2007089904A2 - Pyridylphenyl compounds for inflammation and immune-related uses - Google Patents

Pyridylphenyl compounds for inflammation and immune-related uses Download PDF

Info

Publication number
WO2007089904A2
WO2007089904A2 PCT/US2007/002790 US2007002790W WO2007089904A2 WO 2007089904 A2 WO2007089904 A2 WO 2007089904A2 US 2007002790 W US2007002790 W US 2007002790W WO 2007089904 A2 WO2007089904 A2 WO 2007089904A2
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
pyridin
methyl
alkyl
occurrence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/002790
Other languages
English (en)
French (fr)
Other versions
WO2007089904A3 (en
Inventor
Jun Jiang
Zhi-Qiang Xia
Junyi Zhang
Gary Bohnert
Shoujun Chen
Yu Xie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synta Phamaceuticals Corp
Original Assignee
Synta Phamaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Phamaceuticals Corp filed Critical Synta Phamaceuticals Corp
Priority to EP07762655.4A priority Critical patent/EP1984338B8/en
Priority to DK07762655.4T priority patent/DK1984338T3/da
Priority to AU2007211276A priority patent/AU2007211276B2/en
Priority to JP2008552512A priority patent/JP5430944B2/ja
Priority to PL07762655T priority patent/PL1984338T3/pl
Priority to CA002640049A priority patent/CA2640049A1/en
Priority to ES07762655T priority patent/ES2403368T3/es
Publication of WO2007089904A2 publication Critical patent/WO2007089904A2/en
Publication of WO2007089904A3 publication Critical patent/WO2007089904A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to biologically active chemical compounds, namely pyridylphenyl derivatives that may be used for immunosuppression or to treat or prevent inflammatory conditions and immune disorders.
  • Inflammation is a mechanism that protects mammals from invading pathogens. However, while transient inflammation is necessary to protect a mammal from infection, uncontrolled inflammation causes tissue damage and is the underlying cause of many illnesses. Inflammation is typically initiated by binding of an antigen to T-cell antigen receptor. Antigen binding by a T-cell initiates calcium influx into the cell via calcium ion channels, such as Ca 2+ -release-activated Ca 2+ channels (CRAC). Calcium ion influx in turn initiates a signaling cascade that leads to activation of these cells and an inflammatory response characterized by cytokine production.
  • CRAC Ca 2+ -release-activated Ca 2+ channels
  • IL-2 lnterleukin 2
  • IL-2 is a cytokine that is secreted by T cells in response to calcium ion influx into the cell.
  • IL-2 modulates immunological effects on many cells of the immune system. For example, it is a potent T cell mitogen that is required for the T cell proliferation, promoting their progression from G1 to S phase of the cell cycle,- it stimulates the growth of NK cells; and it acts as a growth factor to B cells and stimulates antibody synthesis.
  • IL-2 although useful in the immune response, can cause a variety of problems.
  • IL-2 damages the blood-brain barrier and the endothelium of brain vessels.
  • IL-2 is a major central regulator of immune responses. It plays a role in inflammatory reactions, tumour surveillance, and hematopoiesis. It also affects the production of other cytokines, inducing IL-1 , TNF- ⁇ and TNF- ⁇ secretion, as well as stimulating the synthesis of IFN- ⁇ in peripheral leukocytes.
  • T cells that are unable to produce IL-2 become inactive (anergic). This renders them potentially inert to any antigenic stimulation they might receive in the future.
  • agents which inhibit IL-2 production can be used for immunosupression or to treat or prevent inflammation and immune disorders.
  • immunosuppressive drugs such as cyclosporin, FK506, and RS61443.
  • agents that inhibit IL-2 production remain far from ideal.
  • efficacy limitations and unwanted side effects including dose-dependant nephrotoxicity and hypertension
  • IL-5 lnterleukin 5
  • IL-5 a cytokine that increases the production of eosinophils
  • Overproduction of IL-5 is associated with accumulation of eosinophils in the asthmatic bronchial mucosa, a hall mark of allergic inflammation.
  • IL-5 lnterleukin 5
  • IL-4 and IL-13 have been identified as mediators of the hypercontractility of smooth muscle found in inflammatory bowel disease and asthma.
  • IL-4 and IL-13 interleukin 13
  • Granulocyte macrophage-colony stimulating factor is a regulator of maturation of granulocyte and macrophage lineage population and has been implicated as a key factor in inflammatory and autoimmune diseases.
  • Anti-GM-CSF antibody blockade has been shown to ameliorate autoimmune disease.
  • development of new drugs that inhibit the production of GM-CSF would be beneficial to patients with an inflammatory or autoimmune disease.
  • new drugs which overcome one or more of the shortcomings of drugs currently used for immunosuppression or in the treatment or prevention of inflammatory disorders, allergic disorders and autoimmune disorders. Desirable properties of new drugs include efficacy against diseases or disorders that are currently untreatable or poorly treatable, new mechanism of action, oral bioavailability and/or reduced side effects.
  • This invention meets the above-mentioned needs by providing certain pyridylphenyl derivatives that inhibit the activity of CRAC ion channels and inhibit the production of IL-2, IL-4, IL-5, IL-13, GM-CSF, TNF- ⁇ , and IFN ⁇ . These compounds are particularly useful for immunosuppression and/or to treat or prevent inflammatory conditions and immune disorders.
  • the invention relates to compounds of formula (I):
  • Y is a monocyclic optionally substituted aryl or a monocyclic optionally substituted heteroaryl
  • L is a linker selected from the group consisting of -NRCR 2 -, -CR 2 NR-, -C(O)-, -NR-C(O)-, -C(O)-NR-, -OC(O)-, -C(O)O-, -C(S)-, -NR-C(S)-, -C(S)-NR-; one of Xi or X 2 is CH or CZ and the other is N; each Z is independently selected from the group consisting of a lower alkyl, a lower haloalkyl, a halo, a lower alkoxy, a lower alkyl sufanyl, -S(O) p -alkyl, -C(O)NRR, -(CH 2 ) k NRR, -(CH 2 ) k OR, -(CH 2 )kSR, cyano, nitro, or lower haloalkoxy;
  • R for each occurrence is independently selected from -H or an alkyl
  • R3 is H, an alkyl, a haloalkyl, a halo, a haloalkoxy, -OR 5 , -SR5, or -NR 6 R 7 ;
  • R 4 is a halo, a haloalkyl, cyano, nitro, -C(O)R 5 , -C(O)OR 5 , -C(O)SR 5 , -C(O)NR 9 Ri 0 , -C(S)R 5 , -C(S)OR 5 , -C(S)SR 5 , -C(S)NR 6 R 7 .
  • R 5 for each occurrence, is independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl;
  • R 6 and R 7 for each occurrence are, independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl; or R 6 and R 7 taken together with the nitrogen to which they are attached are an optionally substituted heterocyclyl or optionally substituted heteroaryl;
  • R 8 for each occurrence, is independently -H, a halo, an alkyl, -OR 5 , -NR 6 R 7 , -C(O)R 5 , -C(O)OR 5 , or -C(O)NR 6 R 7 ;
  • R9 and R10 for each occurrence are, independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted 5- to 14-membered cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted aralkyl, an optionally substituted heteraralkyl, or an optionally substituted heteroaryl selected from the group consisting of an optionally substituted pyridinyl, an optionally substituted thienyl, an optionally substituted pyrrolyl, an optionally substituted oxazolyl, an optionally substituted imidazolyl, an optionally substituted indolizinyl, an optionally substituted isoxazolyl, an optionally substituted pyrazolyl, an optionally substituted isothiazolyl, an optionally substituted pyridazinyl,
  • a compound of the invention or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof is particularly useful inhibiting immune cell (e.g., T-cells and/or B-cells) activation (e.g., activation in response to an antigen).
  • a compound of the invention or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof can inhibit the production of certain cytokines that regulate immune cell activation.
  • a compound of the invention or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof can inhibit the production of IL-2, IL-4, IL-5, IL-13, GM-CSF, TNF- ⁇ , INF- ⁇ or combinations thereof.
  • a compound of the invention or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof can modulate the activity of one or more ion channel involved in activation of immune cells, such as CRAC ion channels.
  • a compound of the invention or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof is particularly useful for immunosuppression or for treating or preventing inflammatory conditions, allergic disorders, and immune disorders.
  • compositions comprising a compound of the invention or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof; and a pharmaceutically acceptable carrier or vehicle. These compositions may further comprise additional agents. These compositions are useful for immunosuppression and treating or preventing inflammatory conditions, allergic disorders and immune disorders.
  • the invention further encompasses methods for treating or preventing inflammatory conditions, allergic disorders, and immune disorders, comprising administering to a subject in need thereof an effective amount of a compound of the invention or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, or a pharmaceutical composition comprising a compound of the invention or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof.
  • methods may also comprise administering to the subject an additional agent separately or in a combination composition with the compound of the invention or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof.
  • the invention further encompasses methods for suppressing the immune system of a subject, comprising administering to a subject in need thereof an effective amount of a compound of the invention or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, or a pharmaceutical composition comprising a compound of the invention or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof.
  • methods for suppressing the immune system of a subject comprising administering to a subject in need thereof an effective amount of a compound of the invention or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, or a pharmaceutical composition comprising a compound of the invention or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof.
  • the invention further encompasses methods for inhibiting immune cell activation, including inhibiting proliferation of T cells and/or B cells, in vivo or in vitro comprising administering to the cell an effective amount of a compound of the invention or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof or a pharmaceutical composition comprising a compound of the invention or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof.
  • the invention further encompasses methods for inhibiting cytokine production in a cell, (e.g., IL-2, IL-4, IL-5, IL-13, GM-CSF, TNF- ⁇ , and/or INF-y production) in vivo or in vitro comprising administering to a cell an effective amount of a compound of the invention or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof or a pharmaceutical composition comprising a compound of the invention or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof.
  • a cell e.g., IL-2, IL-4, IL-5, IL-13, GM-CSF, TNF- ⁇ , and/or INF-y production
  • the invention further encompasses methods for modulating ion channel activity (e.g., CRAC) in vivo or in vitro comprising administering an effective amount of a compound of the invention or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof or a pharmaceutical composition comprising a compound of the invention or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof.
  • ion channel activity e.g., CRAC
  • All of the methods of this invention may be practice with a compound of the invention alone, or in combination with other agents, such as other immunosuppressive agents, anti-inflammatory agents, agents for the treatment of allergic disorders or agents for the treatment of immune disorders.
  • agents such as other immunosuppressive agents, anti-inflammatory agents, agents for the treatment of allergic disorders or agents for the treatment of immune disorders.
  • an "aromatic ring” or “aryl” means a monocyclic or polycyclic-aromatic ring or ring radical comprising carbon and hydrogen atoms.
  • Suitable aryl groups include, but are not limited to, phenyl, tolyl, anthace ⁇ yl, fluorenyl, indenyl, azulenyl, and naphthyl, as well as benzo-fused carbocyclic moieties such as 5,6,7,8-tetrahydronaphthyl.
  • An aryl group can be unsubstituted or substituted with one or more substituents (including without limitation alkyl (preferably, lower alkyl or alkyl substituted with one or more halo), hydroxy, alkoxy (preferably, lower alkoxy), alkylthio, cyano, halo, amino, and nitro.
  • the aryl group is a monocyclic ring, wherein the ring comprises 6 carbon atoms.
  • alkyl means a saturated straight chain or branched non-cyclic hydrocarbon typically having from 1 to 10 carbon atoms.
  • Representative saturated straight chain alkyls include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl and n-decyl; while saturated branched alkyls include isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, 2-methylbutyl, 3-m ethyl butyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylbutyl, 2,3-dimethylpentyl, 2,4-dimethyl
  • Alkyl groups included in compounds of this invention may be optionally substituted with one or more substituents, such as amino, alkylamino, alkoxy, alkylthio, ⁇ xo, halo, acyl, nitro, hydroxyl, cyano, aryl, alkylaryl, aryloxy, arylthio, arylamino, carbocyclyl, carbocyclyloxy, carbocyclylthio, carbocyclylamino, heterocyclyl, heterocyclyloxy, heterocyclylamino, heterocyclylthio, and the like.
  • substituents such as amino, alkylamino, alkoxy, alkylthio, ⁇ xo, halo, acyl, nitro, hydroxyl, cyano, aryl, alkylaryl, aryloxy, arylthio, arylamino, carbocyclyl, carbocyclyloxy, carbocyclylthio, carbocyclylamin
  • alkylene refers to an alkyl group that has two points of attachment to two moieties (e.g., ⁇ -CH 2 - ⁇ , -(CH 2 CH 2 -),
  • Alkylene groups may be substituted or unsubstituted.
  • An aralkyl group refers to an aryl group that is attached to another moiety via an alkylene linker.
  • Aralkyl groups can be substituted or unsubstituted.
  • alkoxy refers to an alkyl group which is linked to another moiety though an oxygen atom. Alkoxy groups can be substituted or unsubstituted.
  • alkoxyalkoxy refers to an alkoxy group in which the alkyl portion is substituted with another alkoxy group.
  • alky! sulfanyl refers to an alkyl group which is linked to another moiety though a divalent sulfur atom. Alkyl sulfanyl groups can be substituted or unsubstituted.
  • alkylamino refers to an amino group in which one hydrogen atom attached to the nitrogen has been replaced by an alkyl group.
  • dialkylamino refers to an amino group in which two hydrogen atoms attached to the nitrogen have been replaced by alkyl groups, in which the alkyl groups can be the same or different. Alkylamino groups and dialkylamino groups can be substituted or unsubstituted.
  • alkenyl means a straight chain or branched, hydrocarbon radical typically having from 2 to 10 carbon atoms and having at least one carbon-carbon double bond.
  • Representative straight chain and branched alkenyls include vinyl, allyl, 1-butenyl, 2-butenyl, isobutylenyl,
  • Alkenyl groups can be substituted or unsubstituted.
  • alkynyl means a straight chain or branched, hydrocarbonon radical typically having from 2 to 10 carbon atoms and having at lease one carbon-carbon triple bond.
  • Representative straight chain and branched alkynyls include acetylenyl, propynyl, 1-butynyl, 2-butynyl,
  • Alkynyl groups can be substituted or unsubstituted.
  • cycloalkyl means a saturated, mono- or polycyclic alkyl radical typically having from 3 to 10 carbon atoms.
  • Representative cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, adamantly, decahydronaphthyl, octahydropentalene, bicycle[1.1.1]pentanyl, and the like. Cycloalkyl groups can be substituted or unsubstituted.
  • cycloalkenyl means a cyclic non-aromatic alkenyl radical having at least one carbon-carbon double bond in the cyclic system and typically having from 5 to 10 carbon atoms.
  • Representative cycloalkenyls include cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl, cycloheptatrienyl, cyclooctenyl, cyclooctadienyl, cyclooctatrienyl, cyclooctatetraenyl, cyclononenyl, cyclononadienyl, cyclodecenyl, cyclodecadienyl and the like. Cycloalkenyl groups can be substituted or unsubstituted.
  • heterocycle or “heterocyclyl” means a monocyclic or polycyclic heterocyclic ring (typically having 3- to 14-members) which is either a saturated ring or an unsaturated non-aromatic ring.
  • a 3-membered heterocycle can contain up to 3 heteroatoms, and a 4- to 14-membered heterocycle can contain from 1 to about 8 heteroatoms.
  • Each heteroatom is independently selected from nitrogen, which can be quatemized; oxygen; and sulfur, including sulfoxide and sulfone.
  • the heterocycle may be attached via any heteroatom or carbon atom.
  • heterocycles include morpholinyl, thiomorpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrindinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.
  • a heteroatom may be substituted with a protecting group known to those of ordinary skill in the art, for example, the hydrogen on a nitrogen may be substituted with a tert-butoxycarbonyl group.
  • the heterocyclyl may be optionally substituted with one or more substituents (including without limitation a halogen atom, an alkyl radical, or aryl radical). Only stable isomers of such substituted heterocyclic groups are contemplated in this definition.
  • Heterocyclyl groups can be substituted or unsubstituted.
  • heteroaromatic or “heteroaryl” means a monocyclic or polycyclic heteroaromatic ring (or radical thereof) comprising carbon atom ring members and one or more heteroatom ring members (such as, for example, oxygen, sulfur or nitrogen).
  • the heteroaromatic ring has from 5 to about 14 ring members in which at least 1 ring member is a heteroatom selected from oxygen, sulfur and nitrogen.
  • the heteroaromatic ring is a 5 or 6 membered ring and may contain from 1 to about 4 heteroatoms.
  • the heteroaromatic ring system has a 7 to 14 ring members and may contain from 1 to about 7 heteroatoms.
  • heteroaryls include pyridyl, furyl, thienyl, pyrrolyl, oxazolyl, imidazolyl, indolizinyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, triazolyl, pyridinyl, thiadiazolyl, pyrazinyl, quinolyl, isoquniolyl, indazolyl, benzoxazolyl, benzofuryl, benzothiazolyl, indolizinyl, imidazopyridinyl, isothiazolyl, tetrazolyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzoxadiazolyl, indolyl, tetrahydroindolyl
  • a heteroaralkyl group refers to a heteroaryl group that is attached to another moiety via an alkylene linker.
  • Heteroaralkyl groups can be substituted or unsubstituted.
  • halogen or halo means -F, -Cl, -Br or -I.
  • haloalkyl means an alkyl group in which one or more -H is replaced with a halo group.
  • haloalkyl groups include -CF 3 , -CHF 2 , -CCI 3 , -CH 2 CH 2 Br, -CH 2 CH(CH 2 CH 2 Br)CH 3 , -CHICH 3 , and the like.
  • haloalkoxy means an alkoxy group in which one or more -H is replaced with a halo group.
  • haloalkoxy groups include -OCF 3 and -OCHF 2 .
  • Bioisostere and “bioisosteric replacement” have the same meanings as those generally recognized in the art.
  • Bioisosteres are atoms, ions, or molecules in which the peripheral layers of electrons can be considered substantially identical.
  • the term bioisostere is usually used to mean a portion of an overall molecule, as opposed to the entire molecule itself.
  • Bioisosteric replacement involves using one bioisostere to replace another with the expectation of maintaining or slightly modifying the biological activity of the first bioisostere.
  • the bioisosteres in this case are thus atoms or groups of atoms having similar size, shape and electron density.
  • Preferred bioisosteres of esters, amides or carboxylic acids are compounds containing two sites for hydrogen bond acceptance.
  • the ester, amide or carboxylic acid bioisostere is a 5-membered monocyclic heteroaryl ring, such as an optionally substituted 1 H-imidazolyl f an optionally substituted oxazolyl, 1 H-tetrazolyl, [1,2,4]triazolyl, or an optionally substituted [1,2,4]oxadiazolyl.
  • the terms "subject”, “patient” and “animal”, are used interchangeably and include, but are not limited to, a cow, monkey, horse, sheep, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit, guinea pig and human.
  • the preferred subject, patient or animal is a human.
  • lower refers to a group having up to four carbon atoms.
  • a “lower alkyl” refers to an alkyl radical having from 1 to 4 carbon atoms
  • a “lower alkenyl” or “lower alkynyl” refers to an alkenyl or alkynyl radical having from 2 to 4 carbon atoms, respectively.
  • a lower alkoxy or a lower alkyl sulfanyl refers to an alkoxy or a alkyl sulfanyl having from 1 to 4 carbon atoms. Lower substituents are typically preferred.
  • the compounds of the invention are defined herein by their chemical structures and/or chemical names. Where a compound is referred to by both a chemical structure and a chemical name, and the chemical structure and chemical name conflict, the chemical structure is determinative of the compound's identity.
  • Suitable substituents for an alkyl, alkoxy, alkyl sulfanyl, alkylamino, dialkylamino, alkylene, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, aralkyl, heteroaryJ, and heteroarylalkyl groups include any substituent which will form a stable compound of the invention.
  • substituents for an alkyl, alkoxy, alkylsulfanyl, alkylamino, dialkylamino, alkylene, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, aralkyl, heteroaryl, and heteroarylalkyl include an alkyl, alkoxy, alkyl sulfanyl, alkylamino, dialkylamino, an alkenyl, an atkynyl, an cycloalkyl, an cycloalkenyl, an heterocyclyl, an aryl, an heteroaryl, an aralkyl, an heteraralkyl, a haloalkyl, -C(O)NR 13 R 14 , -NRi 5 C(O)R 16 , halo, -ORi 5 , cyano, nitro, haloalkoxy, -C(O)Ri 5 ,
  • R 13 and R 14 for each occurrence are, independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl,- or Ri 3 and R 14 taken together with the nitrogen to which they are attached is optionally substituted heterocyclyl or optionally substituted heteroaryl; and R 15 and R ⁇ for each occurrence are, independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalky
  • heterocyclyl, heteroaryl, or heteroaralkyl group When a heterocyclyl, heteroaryl, or heteroaralkyl group contains a nitrogen atom, it may be substituted or unsubstituted. When a nitrogen atom in the aromatic ring of a heteroaryl group has a substituent the nitrogen may be a quaternary nitrogen.
  • stable refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., therapeutic or prophylactic administration to a subject). Typically, such compounds are stable at a temperature of 40 0 C or less, in the absence of excessive moisture, for at least one week. Such choices and combinations will be apparent to those of ordinary skill in the art and may be determined without undue experimentation.
  • the compounds of the invention containing reactive functional groups also include protected derivatives thereof.
  • "Protected derivatives” are those compounds in which a reactive site or sites are blocked with one ore more protecting groups.
  • Suitable protecting groups for carboxy moieties include benzyl, tert-butyl, and the like.
  • Suitable protecting groups for amino and amido groups include acetyl, tert-butoxycarbonyl, benzyloxycarbonyl, and the like.
  • Suitable protecting groups for hydroxy include benzyl and the like.
  • Other suitable protecting groups are well known to those of ordinary skill in the art and include those found in T. W.
  • compound(s) of this invention refers to a compound of any one of formulas (1) through (II), or Table 1, or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof and also include protected derivatives thereof.
  • prodrug means a derivative of a compound that can hydrolyze, oxidize, or otherwise react under biological conditions (in vitro or in vivo) to provide a compound of this invention. Prodrugs may only become active upon such reaction under biological conditions, but they may have activity in their unreacted forms.
  • prodrugs contemplated in this invention include, but are not limited to, analogs or derivatives of compounds of any one of formulas (I) through (II), or Table 1 that comprise biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzabfe esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues.
  • Other examples of prodrugs include derivatives of compounds of any one of formulas (I) through (II), or of Table 1 that comprise -NO, -NO2, -ONO, or -ONO 2 moieties.
  • Prodrugs can typically be prepared using well-known methods, such as those described by 1 BURGER'S MEDICINAL CHEMISTRY AND DRUG DISCOVERY (1995) 172-178, 949-982 (Manfred E. Wolff ed., 5 th ed), the entire teachings of which are incorporated herein by reference.
  • biohydrolyzable amide means an amide, ester, carbamate, carbonate, ureide, or phosphate analogue, respectively, that either: 1 ) does not destroy the biological activity of the compound and confers upon that compound advantageous properties in vivo, such as uptake, duration of action, or onset of action; or 2) is itself biologically inactive but is converted in vivo to a biologically active compound.
  • biohydrolyzable amides include, but are not limited to, lower alkyl amides, ⁇ -amino acid amides, alkoxyacyl amides, and alkylaminoalkylcarbonyl amides.
  • biohydrolyzabfe esters include, but are not limited to, lower alkyl esters, alkoxyacyloxy esters, alkyl acylamino alkyl esters, and choline esters.
  • biohydrolyzable carbamates include, but are not limited to, lower alkylamines, substituted ethylenediamines, aminoacids, hydroxyalkylamines, heterocyclic and heteroaromatic amines, and polyether amines.
  • the term "pharmaceutically acceptable salt,” is a salt formed from an acid and a basic group of one of the compounds of any one of formulas (I) through (II) or of Table 1.
  • Illustrative salts include, but are not limited, to sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfo ⁇ ate, benzenesulfonate, p-toluenesulfonate, and pamoate (i.
  • “pharmaceutically acceptable salt” also refers to a salt prepared from a compound of any one of formulas (I) through (II) or Table 1 having an acidic functional group, such as a carboxylic acid functional group, and a pharmaceutically acceptable inorganic or organic base.
  • Suitable bases include, but are not limited to, hydroxides of alkali metals such as sodium, potassium, and lithium; hydroxides of alkaline earth metal such as calcium and magnesium; hydroxides of other metals, such as aluminum and zinc; ammonia, and organic amines, such as unsubstituted or hydroxy-substituted mono-, di-, or trialkylamines; dicyclohexylamine; tributyl amine; pyridine; N-methyl,N-ethy!amine; diethylamine; triethylamine; mono-, bis-, or tris-(2-hydroxy-lower alkyl amines), such as mono-, bis-, or tris-(2-hydroxyethyl)- amine, 2-hydroxy-tert-butylamine, or tris-(hydroxymethyl)methylamine, N, N.-d ⁇ -lower alkyl-N-(hydroxy lower a!kyl)-amines, such as N,N-dimethyl-N-
  • pharmaceutically acceptable salt also refers to a salt prepared from a compound of any one of formulas (I) through (II) or Table 1 having a basic functional group, such as an amino functional group, and a pharmaceutically acceptable inorganic or organic acid.
  • Suitable acids include, but are not limited to, hydrogen sulfate, citric acid, acetic acid, oxalic acid, hydrochloric acid, hydrogen bromide, hydrogen iodide, nitric acid, phosphoric acid, isonicotinic acid, lactic acid, salicylic acid, tartaric acid, ascorbic acid, succinic acid, maleic acid, besylic acid, fumaric acid, gluconic acid, glucaronic acid, saccharic acid, formic acid, benzoic acid, glutamic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid.
  • solvate is a solvate formed from the association of one or more solvent molecules to one or more molecules of a compound of any one of formulas (I) through (II) or Table 1.
  • solvate includes hydrates (e.g., hemi-hydrate, mono-hydrate, dihydrate, trihydrate, tetrahydrate, and the like).
  • the term "ciathrate” means a compound of the present invention or a salt thereof in the form of a crystal lattice that contains spaces (e.g., channels) that have a guest molecule (e.g., a solvent or water) trapped within.
  • the term "asthma” means a pulmonary disease, disorder or condition characterized by reversible airway obstruction, airway inflammation, and increased airway responsiveness to a variety of stimuli.
  • Immunosuppression refers to impairment of any component of the immune system resulting in decreased immune function. This impairment may be measured by any conventional means including whole blood assays of lymphocyte function, detection of lymphocyte proliferation and assessment of the expression of T cell surface antigens.
  • the antisheep red blood cell (SRBC) primary (IgM) antibody response assay (usually referred to as the plaque assay) is one specific method. This and other methods are described in Luster, M.I., Portier, C, Pait, D.G., White, K.L., Jr., Gennings, C, Munson, A.E., and Rosenthal, GJ. (1992).
  • the term "immune disorder” and like terms means a disease, disorder or condition caused by the immune system of an animal, including autoimmune disorders.
  • Immune disorders include those diseases, disorders or conditions that have an immune component and those that are substantially or entirely immune system-mediated.
  • Autoimmune disorders are those wherein the animal's own immune system mistakenly attacks itself, thereby targeting the cells, tissues, and/or organs of the animal's own body.
  • the autoimmune reaction is directed against the nervous system in multiple sclerosis and the gut in Crohn's disease.
  • systemic lupus erythematosus affected tissues and organs may vary among individuals with the same disease.
  • One person with lupus may have affected skin and joints whereas another may have affected skin, kidney, and lungs. Ultimately, damage to certain tissues by the immune system may be permanent, as with destruction of insulin-producing cells of the pancreas in Type 1 diabetes mellitus.
  • autoimmune disorders of the nervous system e.g., multiple sclerosis, myasthenia gravis, autoimmune neuropathies such as Guillain-Barre, and autoimmune uveitis
  • autoimmune disorders of the blood e.g., autoimmune hemolytic anemia, pernicious anemia, and autoimmune thrombocytopenia
  • autoimmune disorders of the blood vessels e.g., temporal arteritis, anti-phospholipid syndrome, vasculitides such as Wegener's granulomatosis, and Behcet's disease
  • autoimmune disorders of the skin e.g., psoriasis, dermatitis herpetiformis, pemphigus vulgaris, and vitiligo
  • autoimmune disorders of the gastrointestinal system e.g., Crohn's disease, ulcerative colitis, primary biliary cirrhosis, and autoimmune hepatitis
  • Hashimoto's thyroiditis, autoimmune oophoritis and orchitis, and autoimmune disorder of the adrenal gland include connective tissue and musculoskeletal system diseases) (e.g., rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis, dermatomyositis, spondyloarthropathies such as ankylosing spondylitis, and Sjogren's syndrome).
  • connective tissue and musculoskeletal system diseases e.g., rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis, dermatomyositis, spondyloarthropathies such as ankylosing spondylitis, and Sjogren's syndrome.
  • other immune system mediated diseases such as graft-versus-host disease and allergic disorders, are also included in the definition of immune disorders
  • Treatment of an immune disorder refers to administering a compound or a composition of the invention to a subject, who has an immune disorder, a symptom of such a disease or a predisposition towards such a disease, with the purpose to cure, relieve, alter, affect, or prevent the autoimmune disorder, the symptom of it, or the predisposition towards it.
  • allergic disorder means a disease, condition or disorder associated with an allergic response against normally innocuous substances. These substances may be found in the environment (such as indoor air pollutants and aeroallergens) or they may be non-environmental (such as those causing dermatological or food allergies). Allergens can enter the body through a number of routes, including by inhalation, ingestion, contact with the skin or injection (including by insect sting). Many allergic disorders are linked to atopy, a predisposition to generate the allergic antibody IgE. Because IgE is able to sensitize mast cells anywhere in the body, atopic individuals often express disease in more than one organ.
  • allergic disorders include any hypersensitivity that occurs upon re-exposure to the sensitizing allergen, which in turn causes the release of inflammatory mediators.
  • Allergic disorders include without limitation, allergic rhinitis (e.g., hay fever), sinusitis, rhinosinusitis, chronic or recurrent otitis media, drug reactions, insect sting reactions, latex reactions, conjunctivitis, urticaria, anaphylaxis and anaphylactoid reactions, atopic dermatitis, asthma and food allergies.
  • an "inflammatory disorder” means a disease, disorder or condition characterized by inflammation of body tissue or having an inflammatory component. These include local inflammatory responses and systemic inflammation. Examples of such inflammatory disorders include: transplant rejection, including skin graft rejection; chronic inflammatory disorders of the joints, including arthritis, rheumatoid arthritis, osteoarthritis and bone diseases associated with increased bone resorption; inflammatory bowel diseases such as ileitis, ulcerative colitis, Barrett's syndrome, and Crohn's disease; inflammatory lung disorders such as asthma, adult respiratory distress syndrome, and chronic obstructive airway disease; inflammatory disorders of the eye including corneal dystrophy, trachoma, onchocerciasis, uveitis, sympathetic ophthalmitis and endophthalmitis; chronic inflammatory disorders of the gums, including gingivitis and periodontitis; tuberculosis; leprosy; inflammatory diseases of the kidney including uremic
  • a systemic inflammation of the body exemplified by gram-positive or gram negative shock, hemorrhagic or anaphylactic shock, or shock induced by cancer chemotherapy in response to pro-inflammatory cytokines, e.g., shock associated with pro-inflammatory cytokines.
  • shock can be induced, e.g., by a chemotherapeutic agent used in cancer chemotherapy.
  • Treatment of an inflammatory disorder refers to administering a compound or a composition of the invention to a subject, who has an inflammatory disorder, a symptom of such a disorder or a predisposition towards such a disorder, with the purpose to cure, relieve, alter, affect, or prevent the inflammatory disorder, the symptom of it, or the predisposition towards it.
  • an "effective amount” is the quantity of compound in which a beneficial outcome is achieved when the compound is administered to a subject or alternatively, the quantity of compound that possess a desired activity in-vivo or in-vitro.
  • a beneficial clinical outcome includes reduction in the extent or severity of the symptoms associated with the disease or disorder and/or an increase in the longevity and/or quality of life of the subject compared with the absence of the treatment.
  • the precise amount of compound administered to a subject will depend on the type and severity of the disease or condition and on the characteristics of the subject, such as general health, age, sex, body weight and tolerance to drugs. It will also depend on the degree, severity and type of inflammatory disorder or autoimmune disorder or the degree of immunosuppression sought.
  • Effective amounts of the disclosed compounds typically range between about 1 mg/mm 2 per day and about 10 grams/mm 2 per day, and preferably between 10 mg/mm 2 per day and about 1 gram/mm 2 .
  • the compounds of the invention may contain one or more chiral centers and/or double bonds and, therefore, exist as stereoisomers, such as double-bond isomers (i.e., geometric isomers), enantiomers, ordiastereomers.
  • the chemical structures depicted herein, including the compounds of this invention encompass all of the corresponding compounds' enantiomers and stereoisomers, that is, both the stereomerically pure form (e.g., geometrically pure, enantiomerically pure, or diastereomerically pure) and enantiomeric, diastereomeric, and geometric isomeric mixtures.
  • stereomerically pure form e.g., geometrically pure, enantiomerically pure, or diastereomerically pure
  • enantiomeric, diastereomeric, and geometric isomeric mixtures e.g., one enantiomer, diastereomer, or geometric isomer will possess superior activity or an improved toxicity or kinetic profile compared to others. In those cases, such enantiomers, diastereomers, and geometric isomers of a compound of this invention are preferred.
  • inhibitor production of IL-2 means inhibiting IL-2 synthesis (e.g. by inhibiting transcription (mRNA expression), or translation
  • IL-2 secretion in a cell that has the ability to produce and/or secrete IL-2 (e.g., T lymphocyte).
  • IL-2 e.g., T lymphocyte
  • inhibiting production of IL-4, IL-5, JL-13, GM-CSF, TNF- ⁇ or INF- ⁇ means inhibiting the synthesis (e.g. by inhibiting transcription, or translation) and/or inhibiting the secretion in a cell that has the ability to produce and/or secrete these cytokines.
  • composition that "substantially" comprises a compound means that the composition contains more than about 80% by weight, more preferably more than about 90% by weight, even more preferably more than about 95% by weight, and most preferably more than about 97% by weight of the compound.
  • a composition that is "substantially free” of a compound means that the composition contains less than about 20% by weight, more preferably less than about 10% by weight, even more preferably less than about 5% by weight, and most preferably less than about 3% by weight of the compound.
  • a reaction that is “substantially complete” means that the reaction contains more than about 80% by weight of the desired product, more preferably more than about 90% by weight of the desired product, even more preferably more than about 95% by weight of the desired product, and most preferably more than about 97% by weight of the desired product.
  • a racemic mixture means about 50% of one enantiomer and about 50% of is corresponding enantiomer relative to all chiral centers in the molecule.
  • the invention encompasses all enantiomerically-pure, enantiomerically-enriched, diastereomerically pure, diastereomerically enriched, and racemic mixtures of the compounds of any one of formulas (I) through (II) or Table 1.
  • Enantiomeric and diastereomeric mixtures can be resolved into their component enantiomers or stereoisomers by well known methods, such as chiral-phase gas chromatography, chiral-phase high performance liquid chromatography, crystallizing the compound as a chiral salt complex, or crystallizing the compound in a chiral solvent.
  • Enantiomers and diastereomers can also be obtained from diastereomerically- or enantiomerically-pure intermediates, reagents, and catalysts by well known asymmetric synthetic methods.
  • the compounds of the invention When administered to a patient, e.g., to a non-human animal for veterinary use or for improvement of livestock, or to a human for clinical use, the compounds of the invention are typically administered in isolated form or as the isolated form in a pharmaceutical composition.
  • isolated means that the compounds of the invention are separated from other components of either (a) a natural source, such as a plant or cell, preferably bacterial culture, or (b) a synthetic organic chemical reaction mixture.
  • the compounds of the invention are purified.
  • purified means that when isolated, the isolate contains at least 95%, preferably at least 98%, of a single compound of the invention by weight of the isolate. Only thqse choices and combinations of substituents that result in a stable structure are contemplated. Such choices and combinations will be apparent to those of ordinary skill in the art and may be determined without undue experimentation.
  • the invention relates to compounds and pharmaceutical compositions that are particularly useful for immunosuppression or to treat or prevent inflammatory conditions, immune disorders, and allergic disorders.
  • One embodiment of the invention relates to compounds of formula (I):
  • Y is a monocyclic optionally substituted aryl or a monocyclic optionally substituted heteroaryl
  • L is a linker selected from the group consisting of -NRCR2-, -CR 2 NR-, -C(OK -NR-C(O)-, -C(O)-NR-, -OC(O)-. -C(O)O-, -C(S)-, -NR-C(S)-, -C(S)-NR-; one of Xi or X 2 is CH or CZ and the other is N; each Z is independently selected from the group consisting of a lower alkyl, a lower haloalkyl, a halo, a lower alkoxy, a lower alkyl sufanyl, -S(O) p -alkyl, -C(O)NRR, -(CH 2 ) k NRR, -(CH 2 ) k OR, -(CH 2 ) k SR, cyano, nitro, or lower haloalkoxy;
  • R for each occurrence is independently selected from — H or an alkyl
  • R 3 is H, an alkyl, a haloalkyl, a halo, a haloalkoxy, -ORs, -SR5, R 4 is a halo, a haloalkyl, cyano, nitro, -C(O)R 5 , -C(O)OR 5 ,
  • R 5 for each occurrence, is independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl;
  • Re and R 7 are, independently, H, an optionally substituted alky!, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl; or R 6 and R 7 taken together with the nitrogen to which they are attached are an optionally substituted heterocyclyl or optionally substituted heteroaryl;
  • R 8 for each occurrence, is independently -H, a halo, an alkyl, -OR 5 , -NR 6 R 7 , -C(O)R 5 , -C(O)OR 5 , or -C(O)NR 6 R 7 ;
  • Rg and R-I 0 for each occurrence are, independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted 5- to 14-membered cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted aralkyl, an optionally substituted heteraralkyl, or an optionally substituted heteroaryl selected from the group consisting of an optionally substituted pyridinyl, an optionally substituted thienyl, an optionally substituted pyrrolyl, an optionally substituted oxazolyl, an optionally substituted imidazolyl, an optionally substituted indolizinyl, an optionally substituted isoxazolyl, an optionally substituted pyrazolyl, an optionally substituted isothiazolyl, an optionally substituted pyrida
  • Another embodiment of the invention relates to compounds of formula (II):
  • Yi is a monocyclic optionally substituted aryl or a monocyclic optionally substituted heteroaryl, provided that Yi is not a substituted isoxazolyl or a substituted 1H-pyrrolyl;
  • Li is a linker selected from the group consisting of -NHCH 2 -, -CH 2 NH-, -NR-C(O)-, -OC(O)-, -C(O)O-, -C(S)-, -NR-C(S)-, or -C(S)-NR-; one of Xi or X2 is CH or CZ and the other is N; each Z is independently selected from the group consisting of a lower alkyl, a lower haloalkyl, a halo, a lower alkoxy, a lower alkyl sufanyl, -S(O) p -alkyl, -C(O)NRR 1 -(CH 2 XNRR, -(CH 2 J k OR, -(CH 2 ) k SR, cyano, nitro, or lower haloalkoxy;
  • R for each occurrence is independently selected from — H or an alkyl
  • R3 is H, an alkyl, a haloalkyl, a halo, a haloalkoxy, -OR 5 , -SR 5 , or -NR 6 R 7 ;
  • R4 is a halo, a haloalkyl, cyano, nitro, -C(O)Rs, -C(O)OR 5 , -C(O)SR 5 , -C(O)NR 9 Ri 0 , -C(S)R 5 , -C(S)OR 5 , -C(S)SR 5 , -C(S)NR 6 R 7 , -C(NR 8 )R 5 , -C(NR 8 )OR 5 , -C(NR 8 )SR 5 , -C(NR 8 )NR 6 R 7 , -S(O) P R 5> -S(O)pNR 5r -S(O)pOR 5> -P(O)(ORs) 2 , -OP(O)(ORs) 2 , -P(O)(R 5 ) 2 , an optionally substituted heterocyclyl, or an optionally substituted heteroaryl;
  • R 5 for each occurrence, is independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl;
  • R 6 and R 7 for each occurrence are, independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl; or Re and R 7 taken together with
  • R 8 for each occurrence, is independently -H, a halo, an alkyl, -OR 5 , -NR 6 R 7 , -C(O)R 5 , -C(O)OR 5 , or -C(O)NR 6 R 7 ;
  • Rg and Rio for each occurrence are, independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted 5- to 14-membered cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted aralkyl, an optionally substituted heteraralkyl, or an optionally substituted heteroaryl selected from the group consisting of an optionally substituted pyridinyl, an optionally substituted thienyl, an optionally substituted pyrrolyl, an optionally substituted oxazolyl, an optionally substituted imidazolyl, an optionally substituted indolizinyl, an optionally substituted isoxazolyl, an optionally substituted pyrazolyl, an optionally substituted isothiazolyl, an optionally substituted pyridazinyl, an
  • Xi is N.
  • X 2 is CH.
  • X 2 is C(CHa).
  • X 2 is N.
  • Xi is CH.
  • Xi is C(CH 3 ).
  • Xi is N; X 2 is CH; Z is methyl; and n is 1. In one embodiment, in compounds represented by formula (I) or (II), X 2 is N; Xi is CH; Z is methyl; and n is 1.
  • n 0.
  • n is 1 and Z is chloro, fluoro, bromo, methyl, methoxy, cyano, nitro, methylsulfanyl, or trifluoromethyl. In one aspect, Z is methyl.
  • n is 2 and each Z is independently chloro, fluoro, bromo, methyl, methoxy, cyano, nitro, methylsulfanyl, or trifluoromethyl.
  • Z is chloro, fluoro, bromo, methyl, methoxy, cyano, nitro, methylsulfanyl, or trifluoromethyl. In one aspect, Z is methyl.
  • R 4 is -C(O)OR5, a haloalkyl, an optionally substituted oxazolyl, an optionally substituted isoxazolyl, an optionally substituted thiazolyl, an optionally substituted imidazolyl, an optionally substituted pyridinyl, an optionally substituted pyrazolyl, an optionally substituted pyrrolyl, an optionally substituted thiophenyl, an optionally substituted furanyl, an optionally substituted thiadiazolyl, an optionally substituted oxadiazolyl, or an optionally substituted tetrazolyl.
  • R 4 is -C(O)ORs, a haloalkyl, an optionally substituted oxazolyl, an optionally substituted thiazolyl, an optionally substituted imidazolyl, an optionally substituted pyridinyl, an optionally substituted pyrazolyl, an optionally substituted pyrrolyl, an optionally substituted thiophenyl, an optionally substituted furanyl, an optionally substituted thiadiazolyl, an optionally substituted oxadiazolyl, or an optionally substituted tetrazolyl.
  • R 4 is oxazol-2-yl, oxazol-5-yl, 3-methyl-isoxazol-5-yl, isoxazol-5-yl, thiazol-2-yl, thiazol-5-yl, [1 ,3,4]oxadiazol-2-yl, [1 ,3,4]thiadiazol-2-yl, trifluoromethyl, pyridin-3-yl, pyridin-2-yl, furan-2-yl, furan-3-yI, thiophen-2-yl, thiophen-3-yl, -C(O)OCH 2 CH 2 OCH 3 , -C(O)OCH 2 CH 2 CH 3 , -C(O)OCH 2 CH 3 , or -C(O)OCH 3 .
  • R 4 is oxazol-2-yl, oxazol-5-yl, thiazol-2-yl, thiazol-5-yl, [1 ,3,4]oxadiazol-2-yl, trifluoromethyl, pyridin-3-yl, pyridin-2-yl, -C(O)OCH 2 CH 2 CH 3 , -C(O)OCH 2 CH 3 , or -C(O)OCH 3 .
  • R 4 is oxazol-2-yl, oxazol-5-yl, thiazol-2-yl, trifluoromethyl, or -C(O)OCH 3 .
  • R4 is oxazol-2-yl. In one aspect, R 4 is oxazol-5-yl. In one aspect, R 4 is thiazol-2-yl. In one aspect, R 4 is thiazol-5-yl. In one aspect, R 4 is [1 ,3.4]oxadiazol-2-yl. In one aspect, R 4 is trifluoromethyl. In one aspect, R 4 is pyridin-3-yl. In one aspect, R 4 is pyridin-2-yl. In one aspect, R 4 is
  • R 4 is -C(O)OCH 3 .
  • R 4 is a blostere of an ester, amide, or carboxylic acid.
  • R 3 is -H 1 chloro, fluoro, bromo, methyl, or methoxy. In one aspect, R 3 is -H 1 chloro, methyl, or methoxy. In one aspect, R 3 is -H. In one aspect, R 3 is chloro. In one aspect, R 3 is fluoro. In one aspect, R 3 is bromo. In one aspect, R 3 is methyl. In one aspect, R 3 is methoxy.
  • Y is an optionally substituted phenyl, an optionally substituted pyridinyl, an optionally substituted pyrazolyl, an optionally substituted pyridazinyl, an optionally substituted isothiazolyl, an optionally substituted thiazolyl, an optionally substituted triazolyl, an optionally substituted oxadiazolyl, an optionally substituted oxazolyl, an optionally substituted isoxazolyl, an optionally substituted thiadiazolyl, or an optionally substituted thiophenyl.
  • Y is an optionally substituted phenyl, an optionally substituted pyridinyl, an optionally substituted pyridazinyl, an optionally substituted isothiazolyl, an optionally substituted thiazolyl, an optionally substituted triazolyl, an optionally substituted oxadiazolyl, an optionally substituted oxazolyl, an optionally substituted isoxazolyl, an optionally substituted thiadiazolyl, or an optionally substituted thiophenyl.
  • Y is an optionally substituted phenyl or an optionally substituted thiadiazolyl.
  • Y is an optionally substituted phenyl.
  • Y is a phenyl substituted with one to two substituents. In one aspect, Y is a phenyl substituted with one to two substituents, wherein the one to two substituents are each independently a lower alkyl or a halo. In one aspect, Y is 2,6-difluorophenyl or 4-methyl-1 ,2,3-thiadiazol-5-yl. In one aspect, Y is a difluorophenyl. In one aspect, Y is 2,6-difluorophenyl. In one aspect, Y is 4-methyl-1 ,2,3-thiadiazol-5-yl. In one aspect, Y is an optionally substituted pyridinyl.
  • Y is an optionally substituted trrazolyl. In one aspect, Y is an optionally substituted oxadiazolyl. In one aspect, Y is an optionally substituted thiazolyl. In one aspect, Y is an optionally substituted oxazolyl. In one aspect, Y is an optionally substituted isoxazolyl. In one aspect, Y is a mono-substituted pyridinyl. In one aspect, Y is a methyl pyridin-2yl or a fluoro pyridin-2yl.
  • L is a linker selected from the group consisting of -NHCH 2 -, -CH 2 NH-, -C(O)-, -NH-C(O)-, -C(O)-NH-, -OC(O)-, -C(O)O-, -C(S)-, -NH-C(S)-, -C(S)-NH-.
  • L is -NHCH2-.
  • L is -CH 2 NH-.
  • L is -C(O)-.
  • L is -C(O)-NH-.
  • L is -OC(O)-.
  • L is -C(O)O-.
  • L is -C(S)-.
  • L is -NH-C(S)-.
  • L is -C(S)-NH-.
  • L is -NR-C(O)-. In one aspect, L is -NH-C(O)-.
  • Y is an optionally substituted phenyl, an optionally substituted pyridinyl, an optionally substituted pyridazinyl, an optionally substituted isothfazolyl, an optionally substituted thiazolyl, an optionally substituted triazolyl, an optionally substituted oxadiazolyl, an optionally substituted oxazolyl, an optionally substituted thiadiazolyl, or an optionally substituted thiophenyl;
  • R 4 is -C(O)OR 4 , a haloalkyl, an optionally substituted oxazolyl, an optionally substituted thiazolyl, an optionally substituted imidazolyl, an optionally substituted pyridinyl, an optionally substituted pyrazolyl, an optionally substituted pyrrolyl, an optionally substituted thiophenyl, an optionally substituted furanyl, an optionally substituted thiadiazol
  • L is -NH-C(O)-.
  • R 3 is — H, chloro, fluoro, bromo, methyl, or methoxy.
  • R 4 is oxazol-2-yl, oxazol-5-yl, thiazol-2-yl, thiazol-5-yl, [1,3,4]oxadiazoI-2-yl, trifluoromethyl, pyridin-3-yl, pyridin-2-yl,
  • Y is a difluorophenyl. In one aspect, Y is 4-methyl-1 ,2,3-thiadiazol-5-yl.
  • Y is 2,6-difluorophenyl or 4-methyl-1 ,2,3-thiadiazol-5-yl; L is -NH-C(O)-; one of Xi orX 2 is CH; R 3 is -H, chloro, methyl, or methoxy; R 4 is oxazol-2-yl, oxazol-5-yl, thiazol-2-yl, trifluoromethyl, or -C(O)OCH 3 ; and n is 0.
  • Yi is an optionally substituted phenyl, an optionally substituted pyridinyl, an optionally substituted pyrazolyl, an optionally substituted pyridazinyl, an optionally substituted isothiazolyl, an optionally substituted thiazolyl, an optionally substituted triazolyl, an optionally substituted oxadiazolyl, an optionally substituted oxazolyl, an optionally substituted isoxazolyl, an optionally substituted thiadiazolyl, or an optionally substituted thiophenyl.
  • Yi is an optionally substituted phenyl, an optionally substituted pyridinyl, an optionally substituted pyridazinyl, an optionally substituted isothiazolyl, an optionally substituted thiazolyl, an optionally substituted triazolyl, an optionally substituted oxadiazolyl, an optionally substituted oxazolyl, an optionally substituted thiadiazolyl, or an optionally substituted thiophenyl.
  • Yi is an optionally substituted phenyl or an optionally substituted thiadiazolyl.
  • Yi is an optionally substituted phenyl.
  • Yi is a phenyl substituted with one to two substituents.
  • Y 1 is a phenyl substituted with one to two substituents, wherein the one to two substituents are each independently a lower alkyl or a halo.
  • Yi is 2,6-difluorophenyl or 4-methyl-1,2,3-thiadiazol-5-yl.
  • Yi is a difluorophenyl.
  • Yi is 2,6-difluorophenyl.
  • Yi is 4-methyl-1,2,3-thiadiazol-5-yl.
  • Y 1 is an optionally substituted pyridinyl.
  • Yi is an optionally substituted triazolyl.
  • Y 1 is an optionally substituted oxadiazolyl. In one aspect, Yi is an optionally substituted thiazolyl. In one aspect, Yi is an optionally substituted oxazolyl. In one aspect, Yi is a mono-substituted pyridinyl. In one aspect, Yi is a methyl pyridin-2yl or a fluoro pyridin-2yl.
  • L 1 is a linker selected from the group consisting of -NHCH 2 -, -CH 2 NH-, -NH-C(O)-, -OC(O)-, -C(O)O-, -C(S)-, -NH-C(S)-, or -C(S)-NH-.
  • L 1 is -NHCH 2 -.
  • L 1 is -CH 2 NH-.
  • OnC aSPeCt 1 L 1 IS -OC(O)-.
  • L 1 is -C(O)O-.
  • L 1 is -C(S)-.
  • L 1 is -NH-C(S)-.
  • L 1 is -C(S)-NH-.
  • L 1 is -NR-C(O)-. In one aspect, L 1 is -NH-C(O)-.
  • Y 1 is an optionally substituted phenyl, an optionally substituted pyridinyl, an optionally substituted pyridazinyl, an optionally substituted isothiazolyl, an optionally substituted thiazolyl, an optionally substituted triazolyl, an optionally substituted oxadiazolyl, an optionally substituted oxazolyl, an optionally substituted thiadiazolyl, or an optionally substituted thiophenyl;
  • R 4 is -C(O)OR 4 , a haloalkyl, an optionally substituted oxazolyl, an optionally substituted thiazolyl, an optionally substituted imidazolyl, an optionally substituted pyridinyl, an optionally substituted pyrazolyl, an optionally substituted pyrrolyl, an optionally substituted thiophenyl, an optionally substituted furanyl, an optionally substituted thiadia
  • L 1 is -NH-C(O)-.
  • R 3 is -H, chloro, fluoro, bromo, methyl, or methoxy.
  • R 4 is oxazol-2-yl, oxazol-5-yl, thiazol-2-yl, thiazol-5-yl, [1 ,3,4]oxadiazol-2-yl, trifluoromethyl, pyridin-3-yl, pyridin-2-yl, -C(O)OCH 2 CH 2 CH 3 , -C(O)OCH 2 CH 3 , or -C(O)OCH 3 .
  • Yi is a difluorophenyl.
  • Yi is 4-methyl-1 ,2,3-thiadiazol-5-yl.
  • Yi is 2,6-difluorophenyl or 4-methyl-1,2,3-thiadiazol-5-yl; Li is -NH-C(O)-; one of Xi or X 2 is CH; R 3 is -H 1 chloro, methyl, or methoxy; R 4 is oxazol-2-yl, oxazol-5-yl, thiazol-2-yI, trifluoromethyl, or -C(O)OCH 3 ; and n is 0.
  • the invention relates to compounds selected from the group consisting of:
  • the invention relates to pharmaceutical compositions that comprise a compound of any one of formulas (I) through (II), or Table 1 , or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, as an active ingredient, and a pharmaceutically acceptable carrier or vehicle.
  • the compositions are useful for immunosuppression or to treat or prevent inflammatory conditions, allergic conditions and immune disorders.
  • the invention relates to methods for immunosuppression or for treating or preventing inflammatory conditions, immune disorders, or allergic disorders in a patient in need thereof comprising administering an effective amount of a compound represented by any one of formulas (I) through (II), or Table 1 , or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof.
  • the invention in another embodiment, relates to methods for immunosuppression or for treating or preventing inflammatory conditions, immune disorders, or allergic disorders in a patient in need thereof comprising administering an effective amount of a pharmaceutical composition that comprises a compound represented by any one of formulas (I) through (II), or in or Table 1, or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof.
  • compounds of any one of formulas (I) through (II), or Table 1 , or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof are particularly useful inhibiting immune cell (e.g., T-cells and/or B-cells) activation (e.g., activation in response to an antigen) and/or T cell and/or B cell proliferation.
  • immune cell activation e.g., T-cells and/or B-cells
  • Indicators of immune cell activation include secretion of IL-2 by T cells, proliferation of T cells and/or B cells, and the like.
  • a compound of any one of formulas (I) through (II) or Table 1 inhibits immune cell activation and/or T cell and/or B cell proliferation in a mammal (e.g., a human).
  • compounds of any one of formula (I) through (II), or Table 1 , or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof can inhibit the production of certain cytokines that regulate immune cell activation.
  • compounds of any one of formulas (I) through (II), or Table 1, or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof can inhibit the production of IL-2, IL-4, IL-5, IL-13, GM-CSF, IFN- ⁇ , TNF- ⁇ and combinations thereof.
  • a compound of any one of formulas (I) through (II), or Table 1 inhibits cytokine production in a mammal (e.g., a human).
  • compounds of any one of formulas (I) through (II), or Table 1 can modulate the activity of one or more ion channel involved in activation of immune cells, such as CRAC ion channels.
  • a compound of any one of formulas (I) through (II) or Table 1 can inhibit the influx of calcium ions into an immune cell (e.g., T cells and/or B cells) by inhibiting the action of CRAC ion channels.
  • an immune cell e.g., T cells and/or B cells
  • a decrease in I CRAC current upon contacting a cell with a compound is one indicator that the compound inhibitions CRAC ion channels.
  • I C R AC current can be measured, for example, using a patch clamp technique, which is described in more detail in the examples below.
  • a compound of any one of formulas (I) through (II) or Table 1 modulates an ion channel in a mammal (e.g., a human).
  • Activation of T-lymphocytes in response to an antigen is dependent on calcium ion oscillations.
  • Calcium ion oscillations in T-lymphocytes are triggered through stimulation of the T-cell antigen receptor, and involve calcium ion influx through the stored-operated Ca 2+ -release-activated Ca 2+ (CRAC) channel.
  • CRAC Ca 2+ -release-activated Ca 2+
  • an effective amount of a compound of any one of formulas (I) through (II) or Table 1, or a pharmaceutically acceptable salt, solvate, clathrate, and prodrug thereof, or a pharmaceutical composition comprising a compound of any one of formulas (I) through (II) or Table 1 , or a pharmaceutically acceptable salt, solvate, clathrate, and prodrug thereof, is administered to a patient in need of immunosuppression or in need of treatment or prevention of an inflammatory condition, an immune disorder, or an allergic disorder.
  • Such patients may be treatment na ⁇ ve or may experience partial or no response to conventional therapies.
  • Responsiveness of a particular inflammatory condition, immune disorder, or allergic disorder in a subject can be measured directly (e.g., measuring blood levels of inflammatory cytokines (such as IL-2, IL-4, IL-5, IL-13, GM-CSF, TNF- ⁇ , IFN-Y and the like) after administration of a compound of this invention), or can be inferred based on an understanding of disease etiology and progression.
  • the compounds of any one of formulas (I) through (II), or Table 1 , or pharmaceutically acceptable salts, solvates, clathrates, and prodrugs thereof can be assayed in vitro or in vivo, for the desired therapeutic or prophylactic activity, prior to use in humans.
  • known animal models of inflammatory conditions, immune disorders, or allergic disorders can be used to demonstrate the safety and efficacy of compounds of this invention.
  • compositions and dosage forms of the invention comprise one or more active ingredients in relative amounts and formulated in such a way that a given pharmaceutical composition or dosage form can be used for immunosuppression or to treat or prevent inflammatory conditions, immune disorders, and allergic disorders.
  • Preferred pharmaceutical compositions and dosage forms comprise a compound of any one of formulas (I) through (II), or Table 1 , or a pharmaceutically acceptable prodrug, salt, solvate, or clathrate thereof, optionally in combination with one or more additional active agents.
  • Single unit dosage forms of the invention are suitable for oral, mucosal (e.g., nasal, sublingual, vaginal, buccal, or rectal), parenteral (e.g., subcutaneous, intravenous, bolus injection, intramuscular, or intraarterial), or transdermal administration to a patient.
  • mucosal e.g., nasal, sublingual, vaginal, buccal, or rectal
  • parenteral e.g., subcutaneous, intravenous, bolus injection, intramuscular, or intraarterial
  • transdermal administration to a patient.
  • dosage forms include, but are not limited to: tablets; caplets; capsules, such as soft elastic gelatin capsules; cachets; troches; lozenges; dispersions; suppositories; ointments; cataplasms (poultices); pastes; powders; dressings; creams; plasters; solutions; patches; aerosols (e.g., nasal sprays or inhalers); gels; liquid dosage forms suitable for oral or mucosal administration to a patient, including suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions, or a water-in-oil liquid emulsions), solutions, and elixirs; liquid dosage forms suitable for parenteral administration to a patient; and sterile solids (e.g., crystalline or amorphous solids) that can be reconstituted to provide liquid dosage forms suitable for parenteral administration to a patient.
  • suspensions e.g., aqueous
  • composition, shape, and type of dosage forms of the invention will typically vary depending on their use.
  • a dosage form suitable for mucosal administration may contain a smaller amount of active ingredient(s) than an oral dosage form used to treat the same indication.
  • This aspect of the invention will be readily apparent to those skilled in the art. See, e.g., Remington's Pharmaceutical Sciences (1990) 18th ed., Mack Publishing, Easton PA.
  • Typical pharmaceutical compositions and dosage forms comprise one or more excipients.
  • Suitable excipients are well known to those skilled in the art of pharmacy, and non-limiting examples of suitable excipients are provided herein. Whether a particular excipient is suitable for incorporation into a pharmaceutical composition or dosage form depends on a variety of factors well known in the art including, but not limited to, the way in which the dosage form will be administered to a patient.
  • oral dosage forms such as tablets may contain excipients not suited for use in parenteral dosage forms.
  • the suitability of a particular excipient may also depend on the specific active ingredients in the dosage form.
  • the decomposition of some active ingredients can be accelerated by some excipients such as lactose, or when exposed to water.
  • Active ingredients that comprise primary or secondary amines e.g., N-desmethylvenlafaxine and N,N-didesmethylvenlafaxine
  • lactose-free means that the amount of lactose present, if any, is insufficient to substantially increase the degradation rate of an active ingredient.
  • Lactose-free compositions of the invention can comprise excipients that are well known in the art and are listed, for example, in the U.S. Pharmocopia (USP) SP (XXI)/NF (XVI).
  • USP U.S. Pharmocopia
  • lactose-free compositions comprise active ingredients, a binder/filler, and a lubricant in pharmaceutically compatible and pharmaceutically acceptable amounts.
  • Preferred lactose-free dosage forms comprise active ingredients, microcrystalline cellulose, pre-gelatinized starch, and magnesium stearate.
  • This invention further encompasses anhydrous pharmaceutical compositions and dosage forms comprising active ingredients, since water can facilitate the degradation of some compounds.
  • water e.g., 5%
  • water is widely accepted in the pharmaceutical arts as a means of simulating long-term storage in order to determine characteristics such as shelf-life or the stability of formulations over time. See, e.g., Jens T. Carstensen (1995) Drug Stability: Principles & Practice, 2d. Ed., Marcel Dekker, NY, NY, 379-80.
  • water and heat accelerate the decomposition of some compounds.
  • the effect of water on a formulation can be of great significance since moisture and/or humidity are commonly encountered during manufacture, handling, packaging, storage, shipment, and use of formulations.
  • Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions.
  • Pharmaceutical compositions and dosage forms that comprise lactose and at least one active ingredient that comprises a primary or secondary amine are preferably anhydrous if substantial contact with moisture and/or humidity during manufacturing, packaging, and/or storage is expected.
  • anhydrous pharmaceutical composition should be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions are preferably packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e.g., vials), blister packs, and strip packs.
  • suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e.g., vials), blister packs, and strip packs.
  • suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e.g., vials), blister packs, and strip packs.
  • suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e.g., vials), blister packs, and strip packs.
  • the invention further encompasses pharmaceutical compositions and dosage forms that comprise one or more compounds that reduce the rate by which an active ingredient will decompose
  • dosage forms of the invention comprise a compound of any one of formulas (I) through (II), or Table 1, or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof in an amount of from about 1 mg to about 1000 mg, preferably in an amount of from about 50 mg to about 500 mg, and most preferably in an amount of from about 75 mg to about 350 mg.
  • the typical total daily dosage of a compound of any one of formulas (I) through (II), or Table 1, or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof can range from about 1 mg to about 5000 mg per day, preferably in an amount from about 50 mg to about 1500 mg per day, more preferably from about 75 mg to about 1000 mg per day. It is within the skill of the art to determine the appropriate dose and dosage form for a given patient.
  • compositions of the invention that are suitable for oral administration can be presented as discrete dosage forms, such as, but are not limited to, tablets (e.g., chewable tablets), caplets, capsules, and liquids (e.g., flavored syrups).
  • dosage forms contain predetermined amounts of active ingredients, and may be prepared by methods of pharmacy well known to those skilled in the art. See generally, Remington's Pharmaceutical Sciences (1990) 18th ed., Mack Publishing, Easton PA.
  • Typical oral dosage forms of the invention are prepared by combining the active ingredient(s) in an admixture with at least one excipient according to conventional pharmaceutical compounding techniques.
  • Excipients can take a wide variety of forms depending on the form of preparation desired for administration.
  • excipients suitable for use in oral liquid or aerosol dosage forms include, but are not limited to, water, glycols, oils, alcohols, flavoring agents, preservatives, and coloring agents.
  • excipients suitable for use in solid oral dosage forms include, but are not limited to, starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents.
  • tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid excipients are employed. If desired, tablets can be coated by standard aqueous or nonaqueous techniques. Such dosage forms can be prepared by any of the methods of pharmacy. In general, pharmaceutical compositions and dosage forms are prepared by uniformly and intimately admixing the active ingredients with liquid carriers, finely divided solid carriers, or both, and then shaping the product into the desired presentation if necessary.
  • a tablet can be prepared by compression or molding.
  • Compressed tablets can be prepared by compressing in a suitable machine the active ingredients in a free-flowing form such as powder or granules, optionally mfxed with an excipient.
  • Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • excipients that can be used in oral dosage forms of the invention include, but are not limited to, binders, fillers, disintegrants, and lubricants.
  • Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl cellulose, pre-gelatinized starch, hydroxypropyl methyl cellulose, (e.g., Nos. 2208, 2906, 2910), microcrystalli ⁇ e cellulose, and mixtures thereof.
  • Suitable forms of microcrystalline cellulose include, but are not limited to, the materials sold as AVlCEL-PH-101 , AVICEL-PH-103 AVICEL RC-581,
  • Suitable anhydrous or low moisture excipients or additives include AVICEL-PH-103J and Starch 1500 LM.
  • fillers suitable for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.
  • the binder or filler in pharmaceutical compositions of the invention is typically present in from about 50 to about 99 weight percent of the pharmaceutical composition or dosage form.
  • Disintegrants are used in the compositions of the invention to provide tablets that disintegrate when exposed to an aqueous environment. Tablets that contain too much disintegrant may disintegrate in storage, while those that contain too little may not disintegrate at a desired rate or under the desired conditions. Thus, a sufficient amount of disintegrant that is neither too much nor too little to detrimentally alter the release of the active ingredients should be used to form solid oral dosage forms of the invention.
  • the amount of disintegrant used varies based upon the type of formulation, and is readily discernible to those of ordinary skill in the art.
  • Typical pharmaceutical compositions comprise from about 0.5 to about 15 weight percent of disintegrant, preferably from about 1 to about 5 weight percent of disintegrant.
  • Disintegrants that can be used in pharmaceutical compositions and dosage forms of the invention include, but are not limited to, agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, other starches, clays, other algins, other celluloses, gums, and mixtures thereof.
  • Lubricants that can be used in pharmaceutical compositions and dosage forms of the invention include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, and mixtures thereof.
  • calcium stearate e.g., magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc
  • hydrogenated vegetable oil e.g., peanut oil, cottonseed oil
  • Additional lubricants include, for example, a syloid silica gel (AEROSIL 200, manufactured by W.R. Grace Co. of Baltimore, MD), a coagulated aerosol of synthetic silica (marketed by Degussa Co. of Piano, TX), CAB-O-SIL (a pyrogenic silicon dioxide product sold by Cabot Co. of Boston, MA), and mixtures thereof. If used at all, lubricants are typically used in an amount of less than about 1 weight percent of the pharmaceutical compositions or dosage forms into which they are incorporated.
  • AEROSIL 200 manufactured by W.R. Grace Co. of Baltimore, MD
  • a coagulated aerosol of synthetic silica marketed by Degussa Co. of Piano, TX
  • CAB-O-SIL a pyrogenic silicon dioxide product sold by Cabot Co. of Boston, MA
  • lubricants are typically used in an amount of less than about 1 weight percent of the pharmaceutical compositions or dosage forms into which they are incorporated.
  • Active ingredients of the invention can be administered by controlled release means or by delivery devices that are well known to those of ordinary skill in the art. Examples include, but are not limited to, those described in U.S. Patent Nos.: 3,845,770; 3,916,899; 3,536,809; 3,598,123; and 4,008,719, 5,674,533, 5,059,595, 5,591,767, 5,120,548, 5,073,543, 5,639,476, 5,354,556, and 5,733,566, each of which is incorporated herein by reference.
  • Such dosage forms can be used to provide slow or controlled-release of one or more active ingredients using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination thereof to provide the desired release profile in varying proportions.
  • Suitable controlled-release formulations known to those of ordinary skill in the art, including those described herein, can be readily selected for use with the active ingredients of the invention.
  • the invention thus encompasses single unit dosage forms suitable for oral administration such as, but not limited to, tablets, capsules, gelcaps, and caplets that are adapted for controlled-release.
  • controlled-release preparations Ideally, the use of an optimally designed controlled-release preparation in medical treatment is characterized by a minimum of drug substance being employed to cure or control the condition in a minimum amount of time.
  • Advantages of controlled-release formulations include extended activity of the drug, reduced dosage frequency, and increased patient compliance.
  • controlled-release formulations can be used to affect the time of onset of action or other characteristics, such as blood levels of the drug, and can thus affect the occurrence of side (e.g., adverse) effects.
  • Controlled-release formulations are designed to initially release an amount of drug (active ingredient) that promptly produces the desired therapeutic effect, and gradually and continually release of other amounts of drug to maintain this level of therapeutic or prophylactic effect over an extended period of time.
  • the drug In order to maintain this constant level of drug in the body, the drug must be released from the dosage form at a rate that will replace the amount of drug being metabolized and excreted from the body.
  • Controlled-release of an active ingredient can be stimulated by various conditions including, but not limited to, pH, temperature, enzymes, water, or other physiological conditions or compounds.
  • a particular extended release formulation of this invention comprises a therapeutically or prophylactically effective amount of a compound of formula (I) through (II), or Table 1, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, in spheroids which further comprise microcrystalline cellulose and, optionally, hydroxypropylmethyl-cellufose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.
  • Such extended release formulations can be prepared according to U.S. Patent No. 6,274,171, the entire teachings of which are incorporated herein by reference.
  • a specific controlled-release formulation of this invention comprises from about 6% to about 40% a compound of any one of formulas (I) through (II), or Table 1 by weight, about 50% to about 94% microcrystalline cellulose, NF, by weight, and optionally from about 0.25% to about 1% by weight of hydroxypropyl-methylcellulose, USP, wherein the spheroids are coated with a film coating composition comprised of ethyl cellulose and hydroxypropylmethylcellulose.
  • Parenteral dosage forms can be administered to patients by various routes including, but not limited to, subcutaneous, intravenous (including bolus injection), intramuscular, and intraarterial. Because their administration typically bypasses patients' natural defenses against contaminants, parenteral dosage forms are preferably sterile or capable of being sterilized prior to administration to a patient. Examples of parenteral dosage forms include, but are not limited to, solutions ready for injection, dry products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection, suspensions ready for injection, and emulsions.
  • Suitable vehicles that can be used to provide parenteral dosage forms of the invention are well known to those skilled in the art. Examples include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, com oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate. Compounds that increase the solubility of one or more of the active ingredients disclosed herein can also be incorporated into the parenteral dosage forms of the invention.
  • Transdermal, topical, and mucosal dosage forms of the invention include, but are not limited to, ophthalmic solutions, sprays, aerosols, creams, lotions, ointments, gels, solutions, emulsions, suspensions, or other forms known to one of skill in the art. See, e.g., Remington's Pharmaceutical Sciences (1980 & 1990) 16th and 18th eds., Mack Publishing, Easton PA and Introduction to Pharmaceutical Dosage Forms (1985) 4th ed., Lea & Febiger, Philadelphia. Dosage forms suitable for treating mucosal tissues within the oral cavity can be formulated as mouthwashes or as oral gels. Further, transdermal dosage forms include "reservoir type" or "matrix type” patches, which can be applied to the skin and worn for a specific period of time to permit the penetration of a desired amount of active ingredients.
  • Suitable excipie ⁇ ts e.g., carriers and diluents
  • other materials that can be used to provide transdermal, topical, and mucosal dosage forms encompassed by this invention are well known to those skilled in the pharmaceutical arts, and depend on the particular tissue to which a given pharmaceutical composition or dosage form will be applied.
  • excipients include, but are not limited to, water, acetone, ethanol, ethylene glycol, propylene glycol, butane-1 ,3-diol, isopropyl myristate, isopropyl palmitate, mineral oil, and mixtures thereof to form lotions, tinctures, creams, emulsions, gels or ointments, which are non-toxic and pharmaceutically acceptable.
  • Moisturizers or humectants can also be added to pharmaceutical compositions and dosage forms if desired. Examples of such additional ingredients are well known in the art. See, e.g., Remington's Pharmaceutical Sciences (1980 &
  • tissue to be treated additional components may be used prior to, in conjunction with, or subsequent to treatment with active ingredients of the invention.
  • penetration enhancers can be used to assist in delivering the active ingredients to the tissue.
  • Suitable penetration enhancers include, but are not limited to: acetone; various alcohols such as ethanol, oleyl, and tetrahydrofuryl; alkyl sulfoxides such as dimethyl sulfoxide; dimethyl acetamide; dimethyl formamide; polyethylene glycol; pyrrolidones such as polyvinylpyrrolidone; Kollidon grades (Povidone, Polyvidone); urea; and various water-soluble or insoluble sugar esters such as Tween 80 (polysorbate 80) and Span 60 (sorbitan monostearate).
  • the pH of a pharmaceutical composition or dosage form, or of the tissue to which the pharmaceutical composition or dosage form is applied may also be adjusted to improve delivery of one or more active ingredients.
  • the polarity of a solvent carrier, its ionic strength, or tonicity can be adjusted to improve delivery.
  • Compounds such as stearates can also be added to pharmaceutical compositions or dosage forms to advantageously alter the hydrophilicity or lipophilicity of one or more active ingredients so as to improve delivery.
  • stearates can serve as a lipid vehicle for the formulation, as an emulsifying agent or surfactant, and as a delivery-enhancing or penetration-enhancing agent.
  • Different salts, hydrates or solvates of the active ingredients can be used to further adjust the properties of the resulting composition.
  • the methods for immunosuppression or for treating or preventing inflammatory conditions and immune disorders in a patient in need thereof can further comprise administering to the patient being administered a compound of this invention, an effective amount of one or more other active agents.
  • active agents may include those used conventionally for immunosuppression or for inflammatory conditions or immune disorders.
  • other active agents may also be those that provide other benefits when administered in combination with the compounds of this invention.
  • other therapeutic agents may include, without limitation, steroids, non-steroidal anti-inflammatory agents, antihistamines, analgesics, immunosuppressive agents and suitable mixtures thereof.
  • both the compounds of this invention and the other drug agent(s) are administered to a subject (e.g., humans, male or female) by conventional methods.
  • the agents may be administered in a single dosage form or in separate dosage forms. Effective amounts of the other therapeutic agents and dosage forms are well known to those skilled in the art. It is well within the skilled artisan's purview to determine the other therapeutic agent's optima! effective-amount range.
  • the effective amount of the compound of this invention is less than its effective amount when the other therapeutic agent is not administered.
  • the effective amount of the conventional agent is less than its effective amount when the compound of this invention is not administered. In this way, undesired side effects associated with high doses of either agent may be minimized.
  • Other potential advantages including without limitation improved dosing regimens and/or reduced drug cost
  • the other therapeutic agent may be a steroid or a non-steroidal anti-inflammatory agent.
  • Particularly useful non-steroidal anti-inflammatory agents include, but are not limited to, aspirin, ibuprofen, diclofenac, naproxen, benoxaprofen, flurbiprofen, fenoprofen, flubufen, ketoprofen, indoprofen, piroprofen, carprofen, oxaprozin, pramoprofen, muroprofen, trioxaprofen, suprofen, aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpinac, mefenamic acid
  • the other therapeutic agent may be an antihistamine.
  • Useful antihistamines include, but are not limited to, loratadine, cetirrzine, fexofenadine, desloratadine, diphenhydramine, chlorpheniramine, chlorcyclizine, pyrilamine, promethazine, terfenadine, doxepin, carbinoxamine, clemastine, tripelennamine, brompheniramine, hydroxyzine, cyclizine, meclizine, cyproheptadine, phenindamine, acrivastine, azelastine, levocabastine, and mixtures thereof.
  • anthihistamines see Goodman & Gilman's The Pharmacological Basis of Therapeutics (2001) 651-57, 10 th ed).
  • Immunosuppressive agents include glucocorticoids, corticosteroids (such as Prednisone or Solumedrol), T cell blockers (such as cyclosporin A and FK506), purine analogs (such as azathioprine (Imuran)), pyrimidine analogs (such as cytosine arabinoside), alkylating agents (such as nitrogen mustard, phenylalanine mustard, buslfan, and cyclophosphamide), folic acid antagonists (such as aminopterin and methotrexate), antibiotics (such as rapamycin, actinomycin D, mitomycin C, puramycin, and chloramphenicol), human IgG, antilymphocyte globulin (ALG), and antibodies (such as anti-CD3 (OKT3), anti-CD4 (OKT4), anti-CD5, anti-CD7, anti-IL-2 receptor, anti-alpha/beta TCR, anti-ICAM-1, anti-CD20 (Ritux
  • the compounds of this invention may be used as research tools (for example, as a positive control for evaluating other potential CRAC inhibitors, or IL-2, IL-4, IL-5, IL-13, GM-CSF, TNF- ⁇ , and/or INF- ⁇ inhibitors).
  • CRAC inhibitors for example, IL-2, IL-4, IL-5, IL-13, GM-CSF, TNF- ⁇ , and/or INF- ⁇ inhibitors.
  • Reagents and solvents used below can be obtained from commercial sources such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA). 1 H-NMR and 13 C-NMR spectra were recorded on a Varian 300MHz NMR spectrometer- Significant peaks are tabulated in the order: ⁇ (ppm): chemical shift, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br s, broad singlet),coupling constants) in Hertz (Hz) and number of protons.
  • ⁇ ppm
  • Patch clamp experiments were performed in the tight-seal whole-cell configuration at 21-25°C.
  • High resolution current recordings were acquired by a computer-based patch clamp amplifier system (EPC-9, HEKA, Lambrecht, Germany).
  • Patch pipettes had resistances between 2-4 M ⁇ after filling with the standard intracellular solution.
  • voltage ramps 50-200 ms duration spanning the voltage range of -100 to +100 mV were delivered at a rate of 0.5 Hz over a period of 300-400 seconds. All voltages were corrected for a liquid junction potential of 10 mV between external and internal solutions when using glutamate as the intracellular anion. Currents were filtered at 2.9 kHz and digitized at 10 ⁇ s intervals.
  • Capacitive currents and series resistance were determined and corrected before each voltage ramp using the automatic capacitance compensation of the EPC-9.
  • the low resolution temporal development of membrane currents was assessed by extracting the current amplitude at -80 mV or +80 mV from individual ramp current records.
  • Compounds of the invention can also be prepared as in U.S. Application No. 10/897,681, filed July 22, 2004 and U.S. Application No. — entitled “Compounds for Inflammation and Immune-Related Uses," by Lijun Sun, etal., filed on January 6, 2006, the entire teachings of which are incorporated herein by reference.
  • Compounds having -CH 2 -NH- or -NH-CH2- linkers can be prepared by contacting compounds having -NHC(S)- or -C(S)NH- linkers with Raney Ni.
  • compounds of the invention having a -CH 2 -NH- or — NH-CH2- linker can be prepared by reducing a compound having a -C(O)-NH- or -NH-C(O)- linker, respectively, with, for example, sodium borohydride (see U.S. Patent Application No. 10/897,681, filed on July 22, 2004, the entire teachings of which are incorporated herein by reference).
  • Compounds of the invention having -C(O)- linkers can be prepared by a Friedel-Craft acylation reaction, for example, by reacting a pyradinyl derivative (XXIII) with an acid chloride (XXIV) in the presence of AICI 3 to form an intermediate which can then be reacted with an [1 ,3,2]dioxaborolan-2-yl-aryl or -heteroaryl (XXV) in the presence of a palladium catalyst and a base to form a compound of the invention having a carbonyl linker (XXVI) (see Scheme IV).
  • a Friedel-Craft acylation reaction for example, by reacting a pyradinyl derivative (XXIII) with an acid chloride (XXIV) in the presence of AICI 3 to form an intermediate which can then be reacted with an [1 ,3,2]dioxaborolan-2-yl-aryl or -heteroaryl (XXV
  • Compounds of the invention having -CH 2 -NH- or -NH-CH 2 - linkers can be prepared by contacting compounds having -NHC(S)- or -C(S)NH- linkers with Raney Ni.
  • compounds of the invention having a -CH 2 -NH- or -NH-CH2- linker can be prepared by reducing a compound having a -C(O)-NH- or -NH-C(O)- linker, respectively, with, for example, sodium borohydride.
  • compounds that have -NHCH 2 - linkers can be prepared by reacting aldehyde (f) with amine (XX) followed by reduction of the shift base with sodium borohydride as shown in Scheme Via (see U.S. Patent Application No. 10/897,681, filed on July 22, 2004, the entire teachings of which are incorporated herein by reference).
  • Jurkat cells were placed in a 96 well plate (0.5 million cells per well in 1% FBS medium) then a test compound of this invention was added at different concentrations. After 10 minutes, the cells were activated with PHA (final concentration 2.5 ⁇ g/mL) and incubated for 20 hours at 37°C under CO 2 . The final volume was 200 ⁇ l_. Following incubation, the cells were centrifuged and the supernatants collected and stored at -70 0 C prior to assaying for IL-2 production. A commercial ELISA kit (IL-2 Eli-pair, Diaclone Research, Besancon, France) was used to detect production of IL-2, from which dose response curves were obtained. The IC 50 value was calculated as the concentration at which 50% of maximum IL-2 production after stimulation was inhibited versus a non-stimulation control.
  • PHA final concentration 2.5 ⁇ g/mL
  • Inhibition of other cytokine can be tested in a similar manner using a commercially available ELISA kit for each cytokine.
  • EXAMPLE 3 PATCH CLAMP STUDIES OF INHIBITION OF I CRAC CURRENT IN RBL CELLS, JURKAT CELLS, AND PRIMARY T CELLS
  • a whole cell patch clamp method is used to examine the effects of a compound of the invention on a channel that mediates l crac -
  • a baseline measurement is established for a patched cell.
  • a compound to be tested is perfused (or puffed) to cells in the external solution and the effect of the compound on l crac is measured.
  • a compound that modulates l C rac ( e -9-, inhibits) is a compound that is useful in the invention for modulating CRAC ion channel activity.
  • Rat basophilic leukemia cells (RBL-2H3) were grown in DMEM media supplemented with 10% fetal bovine serum in an atmosphere of 95% air/5% CO 2 . Cells were seeded on glass coverslips 1-3 days before use.
  • Electrodes (2-5 M ⁇ in resistance) were fashioned from borosilicate glass capillary tubes (Sutter Instruments, Novato, Ca). The recordings were done at room temperature.
  • the solution was kept on ice and shielded from light before the experiment was preformed. Extracellular solution
  • Each compound was diluted from a 10 mM stock in series using DMSO.
  • the final DMSO concentration was always kept at 0.1 %.
  • IcRAc currents were monitored every 2 seconds using a 50 msec protocol, where the voltage was ramped from -100 mV to +100 mV. The membrane potential was held at 0 mV between the test ramps. In a typical experiment, the peak inward currents would develop within 50-100 seconds.
  • the cells were perfused with a test compound in the extracellular solution. At the end of an experiment, the remaining I CRAC currents were then challenged with a control compound (SKF96365, 10 ⁇ M) to ensure that the current could still be inhibited.
  • the I CRAC current level was determined by measuring the inward current amplitude at -80 mV of the voltage ramp in an off-line analysis using MATLAB.
  • the I CRAC current inhibition for each concentration was calculated using peak amplitude in the beginning of the experiment from the same cell.
  • the IC 50 value and Hill coefficient for each compound was estimated by fitting all the individual data points to a single Hill equation.
  • the table below shows, the concentration of compounds of the invention which inhibits 50 % of the I CRAC current in RBL cells.
  • Jurkat T cells are grown on glass coverslips, transferred to the recording chamber and kept in a standard modified Ringer's solution of the following composition: NaCI 145mM, KCI 2.8mM, CsCI 1OmM, CaCI 2 1OmM, MgCI 2 2mM, glucose 1OmM, HEPES NaOH 1OmM, pH 7.2.
  • the external solution contains 10 mM CaNaR, 11.5 mM glucose and a test compound at various concentrations.
  • the standard intracellular pipette solution contains: Cs-glutamate 145 mM, NaCI 8 mM, MgCI 2 1 mM, ATP 0.5 mM, GTP 0.3 mM, pH 7.2 adjusted with CsOH.
  • the solution is supplemented with a mixture of 10 mM Cs-BAPTA and 4.3-5.3 mM CaCI 2 to buffer [Ca 2+ Ji to resting levels of 100-150 nM.
  • the very first ramps before activation of I C RA C (usually 1 to 3) are digitally filtered at 2 kHz, pooled and used for leak-subtraction of all subsequent current records.
  • the low-resolution temporal development of inward currents is extracted from the leak-corrected individual ramp current records by measuring the current amplitude at -80 mV or a voltage of choice.
  • Primary T cells are obtained from human whole blood samples by adding 100 ⁇ l_ of RosetteSep® human T cell enrichment cocktail to 2 ml_ of whole blood. The mixture is incubated for 20 minutes at room temperature, then diluted with an equal volume of PBS containing 2% FBS. The mixture is layered on top of RosetteSep® DM-L density medium and then centrifuged for 20 minutes at 1200 g at room temperature. The enriched T cells are recovered from the plasma/density medium interface, then washed with PBS containing 2% FBS twice, and used in patch clamp experiments following the procedure described for RBL cells.
  • PBMCs Peripheral blood mononuclear cells
  • PHA phytohemagglutinin
  • CsA cyclosporine A
  • IL-2, IL-4, IL-5, IL-13, GM-CSF, INF- ⁇ and TNF- ⁇ are known inhibitors of cytokine production.
  • the compounds of the invention are expected to be potent inhibitors of IL-2, IL-4, IL-5, IL-13, GM-CSF, INF- ⁇ and TNF- ⁇ in primary human PBM cells.
  • compounds of the invention are not expected to inhibit the anti-inflammatory cytokine, IL-10.
  • RBL cells that have been grown to confluence in a 96 well plate, are incubated at 37°C for at least 2 hours.
  • the medium is replaced in each well with 100 ⁇ L of fresh medium containing 2 ⁇ Lg/mL of anti-DNP IgE.
  • the cells are washed once with PRS (2.6 mM glucose and 0.1% BSA)and 160 ⁇ Lof PRS is added to each well.
  • PRS 2.6 mM glucose and 0.1% BSA
  • 160 ⁇ Lof PRS 160 ⁇ Lof PRS is added to each well.
  • a test compound isadded to a well in a 20 ⁇ L solution at 10X of the desired concentration and incubated for 20 to 40 minutes at 37°C. 20 ⁇ L of 10X mouse anti-lgE (10 ⁇ L ⁇ nL) is added.
  • Compounds of the invention are expected to inhibit degranulation.
  • PBMCs peripheral blood mononuclear cells
  • monocytes peripheral blood mononuclear cells
  • PBLs peripheral blood lymphocytes
  • the non-adherent T cell populations are eluted by washing of the columns with additional media.
  • the T cell preparations are centrifuged, resuspended in 5 ml of incomplete RPMI, and counted using a hemocytometer.
  • ⁇ l aliquots of the cell suspensions are placed on the membrane (pore size 5 ⁇ m) of a Neuroprobe ChemoTx 96 well chemotaxis unit that have been affixed over wells containing 10 ng/ml MIP-1 ⁇ in HHBSS.
  • the T cells are allowed to migrate for 2 hr at 37 0 C, after which the apical surface of the membrane is wiped clean of cells.
  • the chemotaxis units are then placed in a CytoFlour 4000 (PerSeptive BioSystems) and the fluorescence of each well measured (excitation and emission wavelengths of 450 and 530 nm, respectively).
  • the number of migrating cells in each well is determined from a standard curve generated from measuring the fluorescence of serial two-fold dilutions of the labeled cells placed in the lower wells of the chemotaxis unit prior to affixing the membrane.
  • Compounds of the invention are expected to inhibit chemotactic response of T cells.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
PCT/US2007/002790 2006-01-31 2007-01-31 Pyridylphenyl compounds for inflammation and immune-related uses Ceased WO2007089904A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP07762655.4A EP1984338B8 (en) 2006-01-31 2007-01-31 Pyridylphenyl compounds for inflammation and immune-related uses
DK07762655.4T DK1984338T3 (da) 2006-01-31 2007-01-31 Pyridylphenylforbindelser til inflammations- og immunrelaterede anvendelser
AU2007211276A AU2007211276B2 (en) 2006-01-31 2007-01-31 Pyridylphenyl compounds for inflammation and immune-related uses
JP2008552512A JP5430944B2 (ja) 2006-01-31 2007-01-31 炎症および免疫関連用途のためのピリジルフェニル化合物
PL07762655T PL1984338T3 (pl) 2006-01-31 2007-01-31 Związki pirydylofenylowe do zastosowań związanych z zapaleniami i odpornością
CA002640049A CA2640049A1 (en) 2006-01-31 2007-01-31 Pyridylphenyl compounds for inflammation and immune-related uses
ES07762655T ES2403368T3 (es) 2006-01-31 2007-01-31 Compuestos de piridilfenilo para la inflamación y usos inmunorrelacionados

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76378206P 2006-01-31 2006-01-31
US60/763,782 2006-01-31

Publications (2)

Publication Number Publication Date
WO2007089904A2 true WO2007089904A2 (en) 2007-08-09
WO2007089904A3 WO2007089904A3 (en) 2008-01-03

Family

ID=38328061

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/002790 Ceased WO2007089904A2 (en) 2006-01-31 2007-01-31 Pyridylphenyl compounds for inflammation and immune-related uses

Country Status (10)

Country Link
US (3) US20070254926A1 (enExample)
EP (1) EP1984338B8 (enExample)
JP (1) JP5430944B2 (enExample)
AU (1) AU2007211276B2 (enExample)
CA (1) CA2640049A1 (enExample)
DK (1) DK1984338T3 (enExample)
ES (1) ES2403368T3 (enExample)
PL (1) PL1984338T3 (enExample)
TW (1) TW200800188A (enExample)
WO (1) WO2007089904A2 (enExample)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010039238A1 (en) * 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
JP2010536761A (ja) * 2007-08-15 2010-12-02 プレジデント アンド フェロウズ オブ ハーバード カレッジ ネクロトーシスのヘテロ環式抑制剤
WO2011042797A1 (en) 2009-10-08 2011-04-14 Icozen Therapeutics Pvt. Ltd. Pyrazole derivatives as modulators of calcium release -activated calcium channel
EP2182808A4 (en) * 2007-08-01 2011-09-21 Synta Pharmaceuticals Corp Pyridine compounds for inflammatory and immune uses
US8134007B2 (en) 2007-05-03 2012-03-13 Pfizer Inc. Pyridine derivatives
WO2012056478A1 (en) 2010-10-30 2012-05-03 Lupin Limited Oxazole and isoxazole crac modulators
WO2013164769A1 (en) 2012-05-02 2013-11-07 Lupin Limited Substituted pyridine compounds as crac modulators
WO2013164773A1 (en) 2012-05-02 2013-11-07 Lupin Limited Substituted pyrazole compounds as crac modulators
WO2014203217A1 (en) 2013-06-21 2014-12-24 Lupin Limited Substituted heterocyclic compounds as crac modulators
WO2014207648A1 (en) 2013-06-24 2014-12-31 Lupin Limited Chromane and chromene derivatives and their use as crac modulators
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
RU2713179C2 (ru) * 2014-02-21 2020-02-04 Фрост Биолоджик, Инк. Антимитотические амиды для лечения рака и пролиферативных заболеваний
WO2020053834A1 (en) 2018-09-14 2020-03-19 Rhizen Pharmaceuticals Sa Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof
CN111163766A (zh) * 2017-08-17 2020-05-15 医肯纳肿瘤学公司 Ahr抑制剂和其用途
WO2025206747A1 (ko) * 2024-03-27 2025-10-02 동국대학교 산학협력단 신규 옥사다이아졸 유도체 및 이를 포함하는 암 예방 또는 치료용 조성물
US12486274B2 (en) 2020-01-13 2025-12-02 Verge Analytics, Inc. Substituted pyrazolo-pyrimidines and uses thereof

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2922797B2 (ja) 1994-10-07 1999-07-26 大日精化工業株式会社 有色絹糸の製造方法
CA2595000C (en) * 2005-01-25 2013-10-15 Synta Pharmaceuticals Corp. Thiophene compounds for inflammation and immune-related uses
EP1998612A4 (en) * 2006-01-25 2010-11-24 Synta Pharmaceuticals Corp SUBSTITUTED BIARYL COMPOUNDS FOR USE AGAINST INFLAMMATION AND IMMUNE DISORDERS
WO2007087441A2 (en) * 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted aromatic compounds for inflammation and immune-related uses
JP2009524683A (ja) 2006-01-25 2009-07-02 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連用途のためのビニル−フェニル誘導体
PL1984338T3 (pl) * 2006-01-31 2013-06-28 Synta Pharmaceuticals Corp Związki pirydylofenylowe do zastosowań związanych z zapaleniami i odpornością
WO2007109362A2 (en) 2006-03-20 2007-09-27 Synta Pharmaceuticals Corp. Benzoimidazolyl-parazine compounds for inflammation and immune-related uses
US8779154B2 (en) * 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
KR101257550B1 (ko) * 2007-09-10 2013-04-24 칼시메디카, 인크 세포내 칼슘을 조절하는 화합물
WO2009076454A2 (en) * 2007-12-12 2009-06-18 Calcimedica, Inc. Compounds that modulate intracellular calcium
CN102256969A (zh) * 2008-08-27 2011-11-23 钙医学公司 调节胞内钙的化合物
US8524763B2 (en) * 2008-09-22 2013-09-03 Calcimedica, Inc. Inhibitors of store operated calcium release
US8143269B2 (en) * 2008-10-03 2012-03-27 Calcimedica, Inc. Inhibitors of store operated calcium release
WO2011034962A2 (en) * 2009-09-16 2011-03-24 Calcimedica Inc. Compounds that modulate intracellular calcium
CA2797533A1 (en) 2010-04-27 2011-11-10 Calcimedica, Inc. Compounds that modulate intracellular calcium
PT2563776T (pt) 2010-04-27 2016-09-19 Calcimedica Inc Compostos que modulam o cálcio intracelular
US10703722B2 (en) 2010-04-27 2020-07-07 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9079891B2 (en) 2010-08-27 2015-07-14 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP5985611B2 (ja) * 2011-05-03 2016-09-06 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連用途のための化合物
US20120316182A1 (en) 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9856240B2 (en) 2011-10-19 2018-01-02 Calcimedica, Inc. Compounds that modulate intracellular calcium
CA2853485A1 (en) * 2011-10-28 2013-05-02 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
CA2978007A1 (en) 2015-02-27 2016-09-01 Calcimedica, Inc. Pancreatitis treatment
DK3331525T3 (da) 2015-08-07 2020-12-14 Calcimedica Inc Anvendelse af CRAC-kanal-inhibitorer til behandling af slagtilfælde og traumatisk hjerneskade
CN118084860A (zh) * 2024-02-06 2024-05-28 中国药科大学 芳酰胺类化合物及其药物组合物和应用

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5059595A (en) 1989-03-22 1991-10-22 Bioresearch, S.P.A. Pharmaceutical compositions containing 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid and their pharmaceutically acceptable salts in controlled-release form active in the therapy of organic mental disturbances
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5354556A (en) 1984-10-30 1994-10-11 Elan Corporation, Plc Controlled release powder and process for its preparation
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5639476A (en) 1992-01-27 1997-06-17 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5674533A (en) 1994-07-07 1997-10-07 Recordati, S.A., Chemical And Pharmaceutical Company Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
WO2005009539A2 (en) 2003-07-23 2005-02-03 Synta Pharmaceuticals, Corp. Compounds for inflammation and immune-related uses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
ID24959A (id) * 1998-01-28 2000-08-31 Shionogi & Co Senyawa-senyawa trisiklik yang baru
GB9825652D0 (en) * 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
US6552188B2 (en) * 2001-06-29 2003-04-22 Kowa Co., Ltd. Unsymmetrical cyclic diamine compound
ES2295553T3 (es) * 2002-02-12 2008-04-16 Smithkline Beecham Corporation Derivados de nicotinamida utiles como inhibidores de p38.
US20040063761A1 (en) * 2002-08-06 2004-04-01 Kuduk Scott D. 2-(biarylalkyl)amino-3-(fluoroalkanoylamino)pyridine derivatives
EP1575918A2 (en) 2002-12-19 2005-09-21 Neurogen Corporation Substituted biaryl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
GB0402137D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0404574D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Amino acids
CN101083985A (zh) * 2004-09-21 2007-12-05 幸讬制药公司 用于炎症及免疫相关用途的化合物
US7165455B2 (en) 2004-12-18 2007-01-23 Honeywell International Inc. Surface acoustic wave sensor methods and systems
NZ556546A (en) * 2005-01-07 2011-02-25 Synta Pharmaceuticals Corp Compounds for inflammation and immune-related uses
WO2007087441A2 (en) * 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted aromatic compounds for inflammation and immune-related uses
EP1998612A4 (en) * 2006-01-25 2010-11-24 Synta Pharmaceuticals Corp SUBSTITUTED BIARYL COMPOUNDS FOR USE AGAINST INFLAMMATION AND IMMUNE DISORDERS
PL1984338T3 (pl) 2006-01-31 2013-06-28 Synta Pharmaceuticals Corp Związki pirydylofenylowe do zastosowań związanych z zapaleniami i odpornością

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5354556A (en) 1984-10-30 1994-10-11 Elan Corporation, Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5059595A (en) 1989-03-22 1991-10-22 Bioresearch, S.P.A. Pharmaceutical compositions containing 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid and their pharmaceutically acceptable salts in controlled-release form active in the therapy of organic mental disturbances
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5639476A (en) 1992-01-27 1997-06-17 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5674533A (en) 1994-07-07 1997-10-07 Recordati, S.A., Chemical And Pharmaceutical Company Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
WO2005009539A2 (en) 2003-07-23 2005-02-03 Synta Pharmaceuticals, Corp. Compounds for inflammation and immune-related uses

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"Pharmaceutical Dosage Forms", 1985, LEA & FEBIGER
"Remington's Pharmaceutical Sciences", 1980, MACK PUBLISHING
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING
DEAN, J.H., HOUSE, R.V., LUSTER, M.I.: "Principles and Methods of Toxicology", 2001, TAYLOR & FRANCIS, article "Immunotoxicology: Effects of, and Responses to, Drugs and Chemicals", pages: 1415 - 1450
GLEN R. HANSON: "Analgesic, Antipyretic and Anti-Inflammatory Drugs in Remington: The Science and Practice of Pharmacy", vol. 11, 1995, pages: 1196 - 1221
GOODMAN, GILMAN'S: "The Pharmacological Basis of Therapeutics", 2001, pages: 651 - 57
JENS T. CARSTENSEN: "Drug Stability: Principles & Practice", 1995, MARCEL DEKKER, pages: 379 - 80
LEWIS, BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 31, 2003, pages 925 - 929
LUSTER, M.I., PORTIER, C., PAIT, D.G., WHITE, K.L., JR., GENNINGS, C., MUNSON, A.E., ROSENTHAL, G.J.: "Risk Assessment in Immunotoxicology I: Sensitivity and Predictability of Immune Tests", FUNDAM. APPL. TOXICOL., vol. 18, 1992, pages 200 - 210, XP024876322, DOI: doi:10.1016/0272-0590(92)90047-L
PAUL A. INSEL: "Analgesic-Antipyretic and Antiinflammatory Agents and Drugs Employed in the Treatment of Gout, in Goodman & Gilman's The Pharmacological Basis of Therapeutics", 1996, pages: 617 - 57
See also references of EP1984338A4
T. W. GREENE: "Protecting Groups in Organic Synthesis", 1981, JOHN WILEY & SONS, INC.

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8134007B2 (en) 2007-05-03 2012-03-13 Pfizer Inc. Pyridine derivatives
EP2182808A4 (en) * 2007-08-01 2011-09-21 Synta Pharmaceuticals Corp Pyridine compounds for inflammatory and immune uses
US8278344B2 (en) 2007-08-15 2012-10-02 The Brigham And Women's Hospital, Inc. Heterocyclic inhibitors of necroptosis
EP2192838A4 (en) * 2007-08-15 2011-07-27 Harvard College HETEROCYCLIC NEKROPTOSIS HEMMER
JP2010536761A (ja) * 2007-08-15 2010-12-02 プレジデント アンド フェロウズ オブ ハーバード カレッジ ネクロトーシスのヘテロ環式抑制剤
US8658689B2 (en) 2007-08-15 2014-02-25 President And Fellows Of Harvard College Heterocyclic inhibitors of necroptosis
US9108955B2 (en) 2007-08-15 2015-08-18 President And Fellows Of Harvard College Heterocyclic inhibitors of necroptosis
WO2010039238A1 (en) * 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
JP2012504605A (ja) * 2008-10-01 2012-02-23 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連使用のための化合物
US10174034B2 (en) 2009-10-08 2019-01-08 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
US10246450B2 (en) 2009-10-08 2019-04-02 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US9944631B2 (en) 2009-10-08 2018-04-17 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US10668051B2 (en) 2009-10-08 2020-06-02 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
EP3299361A1 (en) 2009-10-08 2018-03-28 Rhizen Pharmaceuticals S.A. Pyrazole derivatives as modulators of calcium release-activated calcium channel
US8921364B2 (en) 2009-10-08 2014-12-30 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US9758514B2 (en) 2009-10-08 2017-09-12 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
WO2011042797A1 (en) 2009-10-08 2011-04-14 Icozen Therapeutics Pvt. Ltd. Pyrazole derivatives as modulators of calcium release -activated calcium channel
EA023298B1 (ru) * 2010-10-30 2016-05-31 Люпин Лимитед Оксазольные и изоксазольные производные в качестве модуляторов crac
US9169242B2 (en) 2010-10-30 2015-10-27 Lupin Limited Oxazoline and isoxazoline derivatives as CRAC modulators
AU2011322068B2 (en) * 2010-10-30 2015-11-05 Lupin Limited Oxazoline and isoxazoline derivatives as CRAC modulators
CN103228636B (zh) * 2010-10-30 2016-02-10 印度鲁宾有限公司 噁唑及异噁唑钙释放激活的钙调节剂
CN105566311A (zh) * 2010-10-30 2016-05-11 印度鲁宾有限公司 噁唑及异噁唑钙释放激活的钙调节剂
AP3341A (en) * 2010-10-30 2015-07-31 Lupin Ltd Oxazoline and isoxazoline derivatives as crac modulators
WO2012056478A1 (en) 2010-10-30 2012-05-03 Lupin Limited Oxazole and isoxazole crac modulators
US10292981B2 (en) 2010-10-30 2019-05-21 Lupin Limited Oxazoline and isoxazoline derivatives as CRAC modulators
EP3067347A1 (en) 2010-10-30 2016-09-14 Lupin Limited Oxazoline and isoxazoline derivatives as crac modulators
CN103228636A (zh) * 2010-10-30 2013-07-31 印度鲁宾有限公司 噁唑及异噁唑钙释放激活的钙调节剂
KR101860286B1 (ko) 2010-10-30 2018-05-21 루핀 리미티드 Crac 조절제인 옥사졸린과 이소옥사졸린 유도체
US9737534B2 (en) 2010-10-30 2017-08-22 Lupin Limited Oxazoline and isoxazoline derivatives as CRAC modulators
WO2013164773A1 (en) 2012-05-02 2013-11-07 Lupin Limited Substituted pyrazole compounds as crac modulators
US9399638B2 (en) 2012-05-02 2016-07-26 Lupin Limited Substituted pyridine compounds as CRAC modulators
WO2013164769A1 (en) 2012-05-02 2013-11-07 Lupin Limited Substituted pyridine compounds as crac modulators
US9409898B2 (en) 2012-05-02 2016-08-09 Lupin Limited Substituted pyrazole compounds as CRAC modulators
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
WO2014203217A1 (en) 2013-06-21 2014-12-24 Lupin Limited Substituted heterocyclic compounds as crac modulators
US9725463B2 (en) 2013-06-21 2017-08-08 Lupin Limited Substituted heterocyclic compounds as CRAC modulators
WO2014207648A1 (en) 2013-06-24 2014-12-31 Lupin Limited Chromane and chromene derivatives and their use as crac modulators
US9790231B2 (en) 2013-06-24 2017-10-17 Lupin Limited Chromane and chromene derivatives and their use as CRAC modulators
RU2713179C2 (ru) * 2014-02-21 2020-02-04 Фрост Биолоджик, Инк. Антимитотические амиды для лечения рака и пролиферативных заболеваний
US11555026B2 (en) 2017-08-17 2023-01-17 Ikena Oncology, Inc. AHR inhibitors and uses thereof
CN111163766A (zh) * 2017-08-17 2020-05-15 医肯纳肿瘤学公司 Ahr抑制剂和其用途
EP3668496A4 (en) * 2017-08-17 2021-07-14 Ikena Oncology, Inc. AHR INHIBITORS AND THEIR USES
AU2018319016B2 (en) * 2017-08-17 2023-08-31 Ikena Oncology, Inc. AHR inhibitors and uses thereof
WO2020053834A1 (en) 2018-09-14 2020-03-19 Rhizen Pharmaceuticals Sa Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof
US12486274B2 (en) 2020-01-13 2025-12-02 Verge Analytics, Inc. Substituted pyrazolo-pyrimidines and uses thereof
WO2025206747A1 (ko) * 2024-03-27 2025-10-02 동국대학교 산학협력단 신규 옥사다이아졸 유도체 및 이를 포함하는 암 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
US8710083B2 (en) 2014-04-29
US20070254926A1 (en) 2007-11-01
EP1984338A4 (en) 2010-05-26
PL1984338T3 (pl) 2013-06-28
AU2007211276A1 (en) 2007-08-09
US20100249195A1 (en) 2010-09-30
JP2009525285A (ja) 2009-07-09
US20140187586A1 (en) 2014-07-03
EP1984338B8 (en) 2013-05-22
CA2640049A1 (en) 2007-08-09
DK1984338T3 (da) 2013-04-22
EP1984338A2 (en) 2008-10-29
WO2007089904A3 (en) 2008-01-03
ES2403368T3 (es) 2013-05-17
EP1984338B1 (en) 2013-01-16
AU2007211276B2 (en) 2013-06-06
TW200800188A (en) 2008-01-01
JP5430944B2 (ja) 2014-03-05

Similar Documents

Publication Publication Date Title
EP1984338B1 (en) Pyridylphenyl compounds for inflammation and immune-related uses
AU2006208045B2 (en) Compounds for inflammation and immune-related uses
AU2006211646B2 (en) Compounds for inflammation and immune-related uses
AU2007208239B2 (en) Substituted aromatic compounds for inflammation and immune-related uses
EP2184994B1 (en) Heterocycle-aryl compounds for inflammation and immune-related uses
AU2006208043B2 (en) Thiophene compounds for inflammation and immune-related uses
US8623871B2 (en) Substituted biaryl compounds for inflammation and immune-related uses
US20070275960A1 (en) Phenyl and pyridyl compounds for inflammation and immune-related uses
US20120064121A1 (en) Pyridine compounds for inflammation and immune-related uses
JP2009524677A (ja) 炎症および免疫関連使用用のチアゾールおよびチアジアゾール化合物
AU2012216699A1 (en) Compounds for inflammation and immune-related uses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007211276

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2640049

Country of ref document: CA

Ref document number: 2008552512

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007211276

Country of ref document: AU

Date of ref document: 20070131

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007762655

Country of ref document: EP